lanthanum carbonate has been researched along with lanthanum in 365 studies
| Studies (lanthanum carbonate) | Trials (lanthanum carbonate) | Recent Studies (post-2010) (lanthanum carbonate) | Studies (lanthanum) | Trials (lanthanum) | Recent Studies (post-2010) (lanthanum) |
|---|---|---|---|---|---|
| 390 | 87 | 218 | 5,016 | 96 | 1,241 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (0.55) | 18.2507 |
| 2000's | 124 (33.97) | 29.6817 |
| 2010's | 211 (57.81) | 24.3611 |
| 2020's | 28 (7.67) | 2.80 |
| Authors | Studies |
|---|---|
| Zhang, A; Zhang, Q | 1 |
| Hutchison, AJ | 4 |
| Nelson, R | 1 |
| Albaaj, F; Hutchison, A | 1 |
| Balducci, A; Coen, G; Curic, S; D'Haese, PC; De Broe, ME; Dimkovic, N; Djukanovic, L; Ferreira, A; Freemont, TJ; Hutchison, A; Pejanovic, S; Popovic, M; Sikole, A; Spasovski, GB; Sulkova, S; Sulowicz, W; Swanepoel, C; Torres, A | 1 |
| Amor, J; Palma, A | 1 |
| Bleyer, AJ | 1 |
| Finn, WF; Joy, MS | 2 |
| D'Amico, M; Locatelli, F; Pontoriero, G | 1 |
| Aime, S; Canavese, C; Mereu, C; Nordio, M; Sabbioni, E | 2 |
| Scott, LJ; Swainston Harrison, T | 1 |
| Al-Baaj, F; Hutchison, AJ; Speake, M | 2 |
| Behets, GJ; D'Haese, PC; De Broe, ME; Verberckmoes, SC | 1 |
| Behets, GJ; Bouillon, R; D'Haese, PC; Damment, SJ; Dams, G; De Broe, ME; Vercauteren, SR | 1 |
| Finn, WF; Hladik, G; Joy, MS | 1 |
| Beevers, C; Damment, SJ; Gatehouse, DG | 1 |
| Auchère, D; de Serre Patey, NM; Drüeke, TB; Lacour, B; Lucas, A; Ruellan, N | 1 |
| Damment, SJ; Shen, V | 1 |
| Albaaj, F; Hutchison, AJ | 2 |
| Asmus, G; Backs, W; Hutchison, AJ; Jamar, R; Maes, B; Mohamed, E; Schmieder, R; Vanwalleghem, J; Vosskuhler, A | 2 |
| Behets, GJ; Bervoets, AR; Cox, AG; D'Haese, PC; De Broe, ME; Denton, J; Oste, L; Salomé, M; Verberckmoes, SC | 1 |
| Cases, A | 1 |
| Chen, JB; Chiang, SS; Yang, WC | 1 |
| Behets, GJ; D'Haese, PC; Dams, G; De Broe, ME; Gritters, M | 1 |
| Finch, J; Liapis, H; Slatopolsky, E | 1 |
| Bramall, N; Cox, A; McLeod, C | 1 |
| Behets, GJ; D'Haese, PC; Damment, SJ; De Broe, ME | 1 |
| Rambeck, W | 1 |
| Denton, J; Freemont, AJ; Hoyland, JA | 1 |
| Behets, GJ; Bervoets, AR; Blust, R; D'Haese, PC; Dams, G; De Broe, ME; Geryl, H; Marynissen, R; Oste, L | 1 |
| Brooks, T; Candiani, C; Hudson, JQ; Joy, MS; Kshirsagar, A | 1 |
| Finn, WF | 1 |
| Nair, SR; Prakash, D; Purohit, RD; Sinha, PK; Tyagi, AK | 1 |
| D'Haese, PC; De Broe, ME; Freemont, T; Gelev, S; Gill, M; Jones, C; Masin-Spasovska, J; Sikole, A; Spasovski, GB; Webster, I | 1 |
| Cunningham, J | 1 |
| Chawla, PS; Kochar, MS | 1 |
| Bellinghieri, G; Calò, LA; Monardo, P; Santoro, D; Savica, V | 1 |
| Damment, SJ; Dennis, K; Pennick, M | 1 |
| Cerny, S; Kunzendorf, U | 1 |
| Damment, SJ | 2 |
| D'Haese, P; De Broe, M; Hutchison, AJ | 1 |
| Altmann, P; Barnett, ME; Finn, WF | 1 |
| Kohyama, N; Ono-Ogasawara, M; Otaki, N; Serita, F; Shinohara, Y; Takata, A; Takaya, M; Toya, T; Yoshida, K | 1 |
| Ben-Dov, IZ; Galitzer, H; Ilan, Y; Naveh-Many, T; Pappo, O; Silver, J; Sklair-Levy, M | 1 |
| Brancaccio, D; Cozzolino, M | 5 |
| An, L; Gao, Y; Liu, Y; Xu, S; Yang, T; Zeng, F; Zhang, L; Zhang, T | 1 |
| Freemont, AJ | 1 |
| Drüeke, TB; Joki, N; Lacour, B; Nikolov, IG | 1 |
| David, S; Haller, H; Kirchhoff, T; Meier, M | 1 |
| Orita, H; Sakaguchi, T; Shigematsu, T | 1 |
| Cheng, T; Fang, Z; Han, K; Zhang, Y | 1 |
| Autissier, V; Damment, SJ; Henderson, RA | 1 |
| Damment, SJ; Pennick, M | 2 |
| Gray, IJ; Kluger, R | 1 |
| Bellinghieri, G; Santoro, D; Savica, V | 1 |
| Arruda, JA; Fischer, JH; How, PP; Lau, AH | 1 |
| Aime, S; Canavese, C; Stratta, P | 1 |
| Chen, JY; Chiou, SY; Chuang, CL; Jian, DY; Li, SY | 1 |
| Sprague, SM | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
| Daem, AO; Lefèbvre, D; Lemaitre, V; Vrigneaud, L | 1 |
| Shigematsu, T | 4 |
| Forejt, J; Horácková, M; Hrasková, M; Pádr, R; Pafcugová, J; Szabo, M | 1 |
| Negri, AL | 1 |
| Brancaccio, D; Cozzolino, M; Fallabrino, G; Galassi, A; Gallieni, M; Pasho, S | 1 |
| Hutchison, AJ; Laville, M | 1 |
| Anger, M; Fishbane, S; Martin, KJ; Mehrotra, R; Sprague, SM; Zeig, S | 1 |
| Bronner, F; Damment, SJ; Pennick, M; Slepchenko, BM | 1 |
| Barnett, ME; Hutchison, AJ; Krause, R; Kwan, JT; Siami, GA | 1 |
| Pratt, RD; Smyth, MD | 2 |
| Confer, S; Malluche, HH; Mawad, H; Monier-Faugere, MC; Pratt, RD; Siami, GA; Smith, M; Swanepoel, C; Wang, GH | 1 |
| Rodríguez Portillo, M | 1 |
| Torregrosa Prats, V | 1 |
| Fernandez Giraldez, E; Sánchez González, MC; Valdivielso Revilla, JM | 1 |
| Valdivieso, JM | 1 |
| Malluche, HH; Mawad, H; Monier-Faugere, MC | 1 |
| Spasovski, G | 1 |
| Behets, GJ; Bervoets, AR; Blust, R; D'Haese, PC; Damment, SJ; Dauwe, S; De Broe, ME; Mubiana, VK; Roels, F; Schryvers, D; Verberckmoes, SC; Yang, Z | 1 |
| Abboud, H; Dauphin, M; Finn, W; Qiu, P; Sprague, SM; Zhang, P | 1 |
| Carlson, HE; Ginsburg, KC; Weitzman, SP | 1 |
| Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J | 1 |
| Chen, B; D'Haese, PC; Dams, G; De Broe, ME; De Clerck, N; Neven, E; Persy, V; Postnov, A | 1 |
| Chan, MR; Hinshaw, M; Jaffery, JB; Yevzlin, AS | 1 |
| Koiwa, F; Sato, Y | 1 |
| Joki, N | 1 |
| Shigematsu, T; Tatsuta, K | 1 |
| Kazama, JJ | 1 |
| Taniguchi, M | 1 |
| Kadowaki, D; Maruyama, T | 1 |
| De Vos, JY; Elseviers, M | 1 |
| Alonso, M; Andrés, E; Ballarín, J; Bover, J; Canal, C; Farré, N; Olaya, MT; Quílez, B | 1 |
| Hutchison, AJ; Mohammed, I | 1 |
| Barton Pai, A; Conner, TA; McQuade, CR | 1 |
| Negi, S; Oda, H; Ohura, M; Sakaguchi, T; Shigematsu, T | 1 |
| Barnett, ME; Hutchison, AJ; Krause, R; Siami, GA | 1 |
| Connor, A; Taylor, JE | 1 |
| Ketteler, M | 1 |
| Bacchetta, J; Cochat, P; Morel, Y; Nicolino, M; Plotton, I; Ranchin, B; Vial, T | 1 |
| Montagnac, R; Schillinger, F | 1 |
| Cox, AG; Damment, SJ; Secker, R | 1 |
| Shigematsu, T; Skaguchi, T | 1 |
| Chantrel, F; Faller, B; Muller, C | 1 |
| Abraham, JL; Davis, RL | 1 |
| Craig, JC; Elder, GJ; Navaneethan, SD; Palmer, SC; Strippoli, GF | 1 |
| Kurz, B; Müller, GA | 1 |
| Krause, R; Nath, SD; Pratt, RD; Ross, EA; Sprague, SM; Zhang, P | 1 |
| Pratt, R; Smyth, M; Wilson, R; Zhang, P | 1 |
| Curran, MP; Robinson, DM | 1 |
| Franssen, CF; Huijssoon, M; Ipema, K | 1 |
| Furuhashi, M; Kato, A; Takita, T | 1 |
| Rees, L; Shroff, RC | 1 |
| D'Haese, P; Damment, SJ | 1 |
| Azancot, MA; Bartolomé, J; Sánchez, RR | 1 |
| Adams, W; Faustino, PJ; Khan, MA; Samy, R; Yang, Y; Yu, L | 1 |
| Borrows, R; Chan, WL; Chapman, E; Collings, K; Dale, C; De Waal, S; Moore, J; Patel, V; Rounsley, K; Tanner, J; Turner, E | 1 |
| Manns, B; Pannu, N; Tonelli, M | 1 |
| Alonso Alvarez, MA; Díez Ojeda, B; Medrano Martínez, S | 1 |
| Arruda, JA; How, PP; Lau, AH; Mason, DL | 1 |
| Auchère, D; Beaune, P; Benchitrit, J; Drüeke, TB; Flinois, JP; Joki, N; Lacour, B; Nikolov, IG; Patey, N; Vicca, S; Ziol, M | 1 |
| Grand-Pierre, AE; Larusso, J; Li, Q; Uitto, J | 1 |
| Orita, H; Shigematsu, T; Tanaka, Y; Yamanaka, S; Yoshimoto, W | 1 |
| Hayashi, H; Kiriyama, T; Kumita, S; Machida, M; Sekine, T; Yamaguchi, H | 1 |
| Blanco Rodríguez, I; Pobes Martínez de Salinas, A; Quiñones Ortiz, L; Suárez Laurés, A | 1 |
| Yokoyama, K | 1 |
| Negi, S; Shigematsu, T | 2 |
| Noto, L | 1 |
| Álvarez-Ude, F; Arenas, MD; Gil, MT; Malek, T; Moledous, A; Reig-Ferrer, A | 1 |
| Chacko, Y; Clark, CJ | 1 |
| Epstein, M; Gutiérrez, OM; Isakova, T; Jüppner, H; Keating, LK; Smith, K; Wolf, M | 1 |
| Beer, M; Hofmann, U | 1 |
| Clarkson, MR; Crush, L; Maher, MM; O'Connor, OJ; Plant, W; Shanahan, F | 1 |
| Chen, C; Collins, G; Gao, H; Guo, H; Liu, J; Liu, M; Lu, H; Zhang, C | 1 |
| Buscombe, J; Davenport, A; Fürstenberg, A | 1 |
| Hossack, S; Martin, P; Pierce, D; Poole, L; Robinson, A; Smyth, M; Van Heusen, H | 1 |
| Almirall, J; Betancourt, L; Calvet, X; Esteve, V; López, T; Martínez-Ocaña, JC; Ruiz, A; Valenzuela, MP | 1 |
| Damment, S; Lorenzo, V; Rodriguez, M; Secker, R; Shen, V | 1 |
| Anattiwong, P; Arruda, JA; How, PP; Lau, AH; Mason, DL | 1 |
| Palanco, MA; Pérez Alonso, L | 1 |
| Laville, M | 1 |
| Anil, M; Polat, H; Solak, Y; Tonbul, HZ; Turkmen, K | 1 |
| Filiopoulos, V; Hadjiyannakos, D; Koutis, I; Lazarou, D; Trompouki, S; Vlassopoulos, D | 1 |
| Kerr, PG; Lau, KK; Polkinghorne, KR; Toussaint, ND | 1 |
| Dragone, J; Martin, P; Poole, L; Pratt, R; Robinson, A; Smyth, M; Wang, P | 1 |
| Flanagan, RJ; Handley, SA; Raja, KB; Sharpe, C | 1 |
| Arisaka, H; Nakaoka, A; Shigematsu, T; Tokumoto, A | 1 |
| Galán, A; Gonzalez-Casaus, ML; Gonzalez-Parra, E; Martinez-Calero, A; Navas, V; Ortiz, A; Rodriguez, M | 1 |
| Fujii, H; Fujimori, A; Fukagawa, M; Goto, S; Hasegawa, H; Kamae, I; Kim, JI; Komaba, H; Moriwaki, K; Nishi, S; Nishioka, M; Shibuya, K; Shin, J; Taniguchi, M; Yoshiya, K | 1 |
| Das, A; Dhiman, I; Gasser, U; Nigam, AK | 1 |
| Benchitrit, J; Drüeke, TB; Edelman, A; Guerrera, IC; Joki, N; Jorgetti, V; Lacour, B; Machado dos Reis, L; Maizel, J; Massy, ZA; Nguyen-Khoa, T; Nikolov, IG | 1 |
| Awai, K; Date, S; Komi, M; Morita, K; Nakamura, S; Namimoto, T; Utsunomiya, D; Yamashita, Y; Yanaga, Y | 1 |
| Ketteler, M; Petermann, AT | 1 |
| Matalon, A; Michelis, MF; Vemuri, N | 1 |
| Brunner-Ziegler, S; Fröschl, B; Hiebinger, C; Zsifkovits, J | 1 |
| Moe, SM; Moorthi, RN | 1 |
| Benner, D; Burgess, M; Colson, C; Krishnan, M; Mayne, TJ; Poole, L; Ricketts, K; Smyth, M; Wilson, S | 1 |
| Chantrel, F; Faller, B; Klein, A; Muller, C; Muller, S; Sissoko, A | 1 |
| Akizawa, T; Mizobuchi, M; Nakazawa, A | 1 |
| Akehurst, R; Goldsmith, D; Hodgkins, P; Keith, MS; Park, H; Rascati, KL; Smyth, M | 1 |
| Bonofiglio, R; Coppolino, G; Greco, R; Lofaro, D; Papalia, T; Senatore, M | 1 |
| Dennis, K; Pennick, M; Poole, L; Smyth, M | 1 |
| Abaigar-Luquin, P; Camarero-Temiño, V; Hijazi-Prieto, B; Mercado-Valdivia, V | 1 |
| Delport, PC; Dribusch, U; Gropp, JM; Schmidt, BH; van der Staay, FJ | 1 |
| Bull, MD; Mulgrew, CJ; Shrimanker, R; Thomas, MR | 1 |
| Bover, J; Brenna, I; Ciceri, P; Cozzolino, M; Cusi, D; Elli, F; Gallieni, M; Rizzo, MA; Stucchi, A | 1 |
| Hossack, S; Martin, P; Pierce, D; Robinson, A; Zhang, P | 1 |
| Flanigan, M; Haynes, WG; Kalil, RS; Stanford, W | 1 |
| Keith, MS; Lok, CE; Morton, AR; Soroka, SD; Tolley, K; Vegter, S | 1 |
| Hamano, T | 1 |
| Hanba, Y; Masumoto, A; Moribata, M; Shigemathu, T | 1 |
| Drüeke, TB; Massy, ZA | 1 |
| Kasai, S; Kinoshita, Y; Murata, Y; Sato, K | 1 |
| Allison, MA; Asplin, J; Block, GA; Chertow, GM; Hoofnagle, AN; Kestenbaum, B; Ketteler, M; Kooienga, L; Mannstadt, M; Persky, MS; Smits, G; Spiegel, DM; Thadhani, R; Wheeler, DC; Wolf, M | 1 |
| von Rosenberg, SJ; Wehr, UA | 1 |
| Ginard-Vicens, D; Gomila-Roy, GE; Hemfelt-Minobis, A; Khorrami-Minaei, S; Vila-Navarro, S | 1 |
| Chiyotanda, S; Fujimoto, S; Fukudome, K; Kitamura, K; Sato, Y; Toida, T; Yamada, K | 1 |
| Eriguchi, M; Kitazono, T; Nakano, T; Tanaka, S; Taniguchi, M; Tsuruya, K; Yamada, S; Yoshida, H | 1 |
| Dellanna, F; Reichel, H; Seibt, F | 1 |
| Bruschetta, E; Cozzolino, M; Cusi, D; Galassi, A; Giovenzana, ME; Montanari, E | 1 |
| Evenepoel, P; Meijers, B | 1 |
| de Vries, PA; Laverman, GD; Raghoo, R; van den Hout, JH; Woittiez, AJ | 1 |
| Choi, HY; Lee, HY; Lee, YK; Shin, SK | 1 |
| D'Haese, PC; Hoppe, B; Robijn, S; Verhulst, A; Vervaet, BA | 1 |
| Khan, MA; Shah, RB; Yang, Y; Yu, LX | 1 |
| Bykadi, S; Carlin, AS; Khan, MA; Shah, RB; Yang, Y; Yu, LX | 1 |
| Dolgin, B; Jung, G; Markovich, V; Mogilyansky, D; Puzniak, R; Wisniewski, A | 1 |
| Chen, JH; Chen, XM; Ding, GH; Fan, YP; Liu, ZH; Mei, CL; Ni, ZH; Wang, LN; Wang, M; Xu, J; Yu, XQ; Yuan, FH; Zhang, AP; Zhang, YX | 1 |
| Aljama, P; Almadén, Y; Martín-Malo, A; Ojeda, R; Rodríguez, M; Soriano, S | 1 |
| Black, T; Burbridge, R; Philips, G | 1 |
| Copley, JB; Gill, M; Hutchison, AJ; Poole, L; Wilson, RJ | 1 |
| Iglesias, MÁ; Lucas, C; Vicente, P | 1 |
| Barchi-Chung, A; Contreras, G; Diego, J; Dosch, A; Enfield, G; Gutiérrez, OM; Houston, J; Isakova, T; Lenz, O; Mendez, A; Schiavenato, E; Smith, K; Vargas, G; Wahl, P; Weiner, RB; Wolf, M; Xie, H | 1 |
| Ando, R; Chida, Y; Inoue, A; Ishida, Y; Iwamoto, S; Kikuchi, K; Kimura, H; Ohtsuka, M; Sato, H; Tachibana, K; Takayama, M; Yamada, K; Yoshizaki, Y | 1 |
| Furui, H; Gotoh, J; Hattori, M; Horie, T; Iida, J; Kawamura, A; Kukita, K; Meguro, J; Onodera, K; Tamaki, T; Tsuchihashi, S; Yonekawa, M | 1 |
| Hasegawa, Y; Kamo, Y; Kikuchi, N; Matsuda, E; Sekino, H; Sekino, M; Takeuchi, K | 1 |
| Hong, Z; Ishizu, T; Kaneko, Y; Matsunaga, T; Taru, Y | 1 |
| Ando, R; Chida, Y; Shinoda, T; Suzuki, T; Tagawa, H; Takagi, M; Tanaka, Y; Yamasaki, M | 1 |
| Adachi, T; Ando, R; Fukami, K; Hazama, T; Kaida, Y; Kohno, K; Kusumoto, T; Manabe, R; Nakayama, Y; Okuda, S; Sakai, K; Ueda, S; Wada, Y; Yamagishi, S | 1 |
| Inaba, M; Ito, A; Nitta, K; Otsubo, S; Satoh, S; Tanaka, M; Tominaga, Y; Yajima, A | 1 |
| Hirose, M; Ishida, Y; Izumiya, Y; Ota, S | 1 |
| Kabaya, T; Mitsuhashi, T; Miyajima, S; Nitta, K; Ogawa, T; Ohba, T; Otsuka, K; Shizuku, J; Takahashi, M; Takahashi, N; Yamashita, T | 1 |
| Furuya, R; Hidaka, S; Ishioka, K; Iwagami, M; Kobayashi, S; Maesato, K; Mochida, Y; Moriya, H; Ohtake, T; Oka, M; Tsutsumi, D | 1 |
| Fukagawa, M; Koizumi, M; Komaba, H | 1 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Kondo, F; Kumata, C; Mizobuchi, M; Ogata, H; Ono, N; Uda, S; Yamazaki-Nakazawa, A | 1 |
| Boongird, S; Moazzam, AA | 1 |
| Er, E; Reinacher, M; Thom, N | 1 |
| Bierhals, AJ; Cheng, SC; Dávila-Román, VG; de las Fuentes, L; Dietzen, DJ; Hruska, KA; Ross, W; Rothstein, M; Seifert, ME; Windus, D | 1 |
| Guo, H; Tang, S; Zhang, S; Zhang, X | 1 |
| Elisaf, MS; Kalaitzidis, RG | 1 |
| Baldischweiler, J; Imanidis, G; Kriwet, B; Lanz, M; Schill, J; Stafford, J | 1 |
| Akhtar, J; Chen, B; Wang, H; Wang, R; Yu, C; Zhang, H; Zhao, T | 1 |
| Di, B; Gao, X; Huang, W; Liu, J; Tang, Y; Zhang, F | 1 |
| Fumoto, T; Ikeda, K; Ito, M | 1 |
| Kimura, K; Oishi, D; Sakurada, T; Shibagaki, Y; Yasuda, T | 1 |
| Fan, J; Li, Z; Wen, J; Zhang, C | 1 |
| Behets, GJ; D'Haese, PC; Damment, SJ; Dams, G; De Broe, ME; Martin, P | 1 |
| Goumenos, DS; Papachristou, E; Sonikian, M | 1 |
| Del Vecchio, L; Locatelli, F | 2 |
| Copley, JB; Keith, MS; Preston, P; Wilson, RJ | 2 |
| Akhtar, J; Bing, C; Che, Y; Kezhou, Y; Rong, W; Tingting, Z | 1 |
| Wada, K; Wada, Y | 1 |
| Morís Felgueroso, M; Pinal Fernández, I; Trallero Araguás, E | 1 |
| Agapova, O; Fang, Y; Freedman, BI; Ginsberg, C; Hruska, KA; Malluche, H; Monier-Faugere, MC; Register, TC; Seifert, M; Sugatani, T | 1 |
| Kurita, N; Uchihara, H | 1 |
| Kong, XL; Li, WB; Wang, ZS; Wei, Y | 1 |
| Galani, VJ; Prajapati, VA; Shah, PR | 1 |
| Fukuda, M; Ikeda, Y; Kishi, T; Miyazono, M; Nonaka, Y; Sanai, T; Sato, S; Takashima, T; Yoshizaki, M | 1 |
| Cannata-Andía, J; González, MT; González-Parra, E; Torregrosa, JV | 1 |
| Contreras-Padilla, M; Jimeno-Almazán, A; Vilaplana-García, R | 1 |
| Copley, JB; Keddad, K; Preston, P; Prié, D; Ureña-Torres, P; Wan, H; Wilde, P | 1 |
| Ando, R; Chida, Y; Inagaki, Y; Inoue, A; Ishida, Y; Iwamoto, S; Kikuchi, K; Kimura, H; Ohnishi, T; Ohtsuka, M; Tachibana, K; Takayama, M; Yama, S; Yamada, K | 1 |
| Hara, K; Kishi, Y; Kurosawa, N; Obara, Y; Takada, D; Yamashiro, H | 1 |
| Hida, M; Hyodo, T; Ishii, D; Iwamura, M; Kawakami, J; Kurata, Y; Mikami, N; Wakai, H; Yoshida, K | 1 |
| Fujimoto, T; Furuhashi, M; Harada, M; Kamiya, E; Kato, A; Maruyama, S; Okamoto, M; Suzuki, H; Takita, T; Tamiya, R; Tukada, A | 1 |
| Haruhara, K; Kamejima, S; Kanzaki, G; Mafune, H; Manabe, M; Mashiko, H; Okamoto, H; Yokoo, T | 1 |
| Kumagai, J; Mukai, I; Takahashi, N; Tsuchiya, S; Yoshizawa, T | 1 |
| Iida, A; Matsuo, A; Matsushita, M; Miyamoto, K; Tanimoto, M | 1 |
| Chen, H; Liu, L; Wang, Y; Yang, Y; Zhou, L; Zhu, X | 1 |
| Matsuda, Y; Shigematsu, T; Takahara, Y; Takahashi, S | 1 |
| Barrientos Delgado, A; Berenguer Guirado, R; Florido García, M; Palacios Pérez, A | 1 |
| Brunelli, SM; Copley, JB; Keith, MS; Sibbel, S; Wilson, RJ | 1 |
| Li, L; Sun, QL; Wang, R; Yu, XS; Zhai, CJ; Zhang, LT; Zhou, AY | 1 |
| Anderson, CA; Block, GA; Ix, JH; Persky, MS; Smits, G | 1 |
| Bester, IC; Delport, PC; Erasmus, HL; King, JN; Seewald, W | 1 |
| Barnes, PM; Delport, PC; Erasmus, HL; King, JN; Luus, HG; Speranza, C | 1 |
| Sun, J; Wang, R; Yang, XW; Zhai, CJ | 1 |
| Kawaguchi, K; Kodama, R; Makino, M; Nagasawa, M; Nakamura, H; Shimojo, H | 1 |
| Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Suzuki, H | 1 |
| Kitazono, T; Noguchi, H; Ooboshi, H; Tatsumoto, N; Tokumoto, M; Tsuruya, K; Yamada, S | 1 |
| Imanishi, Y; Inaba, M; Ishimura, E; Nagayama, H; Okuno, S; Shoji, S; Yamada, S | 1 |
| Haratake, J; Hisaoka, M; Matsuyama, A; Ootani, A; Shimajiri, S; Yasunaga, C | 1 |
| D'Haese, PC; Robijn, S; Verhulst, A; Vervaet, BA | 1 |
| Buemi, M; Coppolino, G; Fuiano, G; Lacquaniti, A; Leonello, G; Lucisano, S; Rivoli, L; Santoro, D; Villari, A; Villari, I | 1 |
| Hanafusa, N | 1 |
| Suzuki, H; Takenaka, T; Yamanaka, T; Yoshida, M | 1 |
| Beaubien-Souligny, W; Bell, R; Bezzaoucha, S; Lafrance, JP; Lamarche, C; Ouimet, D; Pichette, V; Vallee, M | 1 |
| Iwatani, Y; Masumoto, AR; Mima, T; Moribata, MK; Nakashima, YM; Negi, S; Ohya, M; Shigematsu, T; Tatsuta, K; Yamanaka, S | 1 |
| Burnier, M; Funk, F; Maillard, M; Malluche, HH; Phan, O; Stehle, JC | 1 |
| Ding, GH; He, Y; Li, J; Li, MM; Liu, D; Mu, CJ; Peng, QP; Wang, XH; Yang, GS; Zhang, X | 1 |
| Lederer, SR; Schmid, H | 1 |
| Hayashi, H; Ichie, T; Sugiura, Y; Sugiyama, T; Suzuki, D | 1 |
| Brewster, UC; Jaffe, PE; Jain, D; Moeckel, G; Valika, AK | 1 |
| Haratake, J; Ohtani, A; Yasunaga, C | 1 |
| Iwamuro, M; Okada, H; Sakae, H | 1 |
| Kobayashi, M; Maruyama, I; Maruyama, K; Tatemichi, S; Yaguchi, A; Yonekubo, S | 1 |
| Floege, J | 1 |
| Kawashima, S; Minakuchi, J; Nagai, K; Tsuchida, K; Yokota, N | 1 |
| Abrisqueta Carrión, J; Ibáñez Cánovas, N; Luján Mompeán, JA; Parrilla Paricio, P; Ruiz Pardo, J | 1 |
| Iwamuro, M; Kimoto, K; Okada, H; Tanaka, T; Urata, H | 1 |
| Akizawa, T; Fukagawa, M; Hirakata, H; Kagimura, T; Kaneda, H; Ogata, H | 1 |
| Liu, X; Lv, L; Su, Y; Wang, X; Zhai, H | 1 |
| Craig, JC; French, R; Gardner, S; Johnson, DW; Mavridis, D; Palmer, SC; Ruospo, M; Strippoli, GF; Tonelli, M | 1 |
| Copley, JB; Garafola, S; Hutchison, AJ; Wilson, RJ | 1 |
| Harada, H; Haratake, J; Hisaoka, M; Matsuyama, A; Shiba, E; Uchihashi, K; Yabuki, K | 1 |
| Matsuda, H; Miyazaki, M; Oka, Y | 1 |
| Benner, D; Bross, R; Jing, J; Kalantar-Zadeh, K; Koontz Parsons, T; Kopple, JD; Kovesdy, CP; Lee, ML; Mehrotra, R; Rhee, CM; St-Jules, DE; Tortorici, AR; You, AS | 1 |
| Anderson, CA; Nguyen, HA; Rifkin, DE | 1 |
| Chang, YM; Chen, IL; Hsu, KS; Huang, YT; Jhen, RN; Kao, JL; Liou, HH; Liu, MC; Shiao, CC; Tsai, SC; Tung, NY; Yang, CL | 1 |
| Ban, S; Imada, H; Kubota, K; Ohshima, S; Satoh, H; Suzuki, S; Ueda, Y | 1 |
| Gregus, Z; Németi, B; Poór, M | 1 |
| Abraham, JL; Everett, JM; Hoda, RS; Hundemer, GL; Lauwers, GY; Misdraji, J; Sanyal, S; Tolkoff-Rubin, N; Yee, E | 1 |
| Ando, A; Iwamuro, M; Kimura, K; Kusumoto, C; Nada, T; Okada, H; Otsuka, F; Tanaka, T; Urata, H; Yamauchi, K | 1 |
| Balcam, S; Harris, K | 1 |
| Cardone, KE; Hudson, JQ; St. Peter, WL; Wazny, LD; Weinhandl, E | 1 |
| Abe, T; Arakane, M; Daa, T; Etoh, T; Gamachi, A; Inomata, M; Kondo, Y; Kusaba, T; Murakami, K; Nagai, T; Nishida, H; Shiraishi, N; Shitomi, Y; Yano, S; Yokoyama, S | 1 |
| Adachi, K; Araki, A; Ishikawa, N; Kinoshita, Y; Komatsu-Fujii, T; Maruyama, R; Mishiro, T; Miyaoka, Y; Onuma, H; Tauchi-Nishi, P; Yamamoto, T | 1 |
| Kobayashi, M; Takeda, H; Tatemichi, S; Yaguchi, A | 1 |
| Amari, Y; Hattori, K; Hirose, Y; Imanishi, M; Maeda, T; Moriya, T; Nishida, S; Sakaguchi, M | 1 |
| Fujii, H; Goto, S; Kono, A; Kono, K; Nakai, K; Nishi, S; Nishii, T | 1 |
| Wang, S; Zhang, C; Zhang, X; Zhao, S | 1 |
| St Peter, WL; Wazny, LD; Weinhandl, ED | 1 |
| Harada, H; Haratake, J; Hirata, K; Hisaoka, M; Matsuyama, A; Shiba, E; Tsuda, Y; Uchihashi, K; Yabuki, K; Yorita, K | 1 |
| Neradova, A; Schumacher, SP; Schurgers, LJ; Vervloet, MG | 1 |
| Eso, Y; Seno, H; Yoshioka, M | 1 |
| Li, H; Lu, X; Wang, F; Wang, S; Xiong, R; Zhang, J | 1 |
| Fukagawa, M; Hida, M; Kakuta, T; Komaba, H; Suga, T; Wada, T | 1 |
| Hasegawa, M; Hayashi, H; Inaguma, D; Ito, E; Koide, S; Takahashi, K; Yuzawa, Y | 1 |
| Iwamuro, M; Kawahara, Y; Kawano, S; Kimoto, K; Okada, H; Tanaka, T; Urata, H | 1 |
| Abe, M; Kitai, M; Maruyama, N; Maruyama, T; Nagura, C; Otsuki, T; Shibahara, N; Tomita, H; Yoshida, Y | 1 |
| Ando, T; Ito, K; Minegishi, A; Nagano, N; Ogawa, T; Tsutsui, T | 1 |
| Iwamuro, M; Okada, H; Tanaka, T; Urata, H | 2 |
| Chen, KH; Hsiao, CC; Lee, CC | 1 |
| Chang, FM; Tarng, DC; Yang, CY | 1 |
| Achenbach, H; Hall, G; Hutchison, A; Thadhani, R; Vergani, A; Whelton, A; Wu, J | 1 |
| Kinoshita, O; Motomura, N; Ono, M; Yamauchi, H | 1 |
| Chen, YQ; Miao, YY; Xia, M; Xu, CM; Zhu, HQ | 1 |
| Gao, Y; Li, Y; Lv, C; Wang, G; Wang, Z | 1 |
| Li, H; Lin, Z; Xie, W; Zhou, T | 1 |
| Badve, SV; Elder, G; Hawley, C; Lioufas, N; Pascoe, E; Pedagogos, E; Toussaint, ND; Valks, A | 1 |
| Awad, C; Gilkison, K; Shaw, E | 1 |
| Fischer, M; Gork, I; Shavit, MM | 1 |
| Oguri, N; Shiratori, Y | 1 |
| Block, GA; Cheung, AK; Flessner, MF; Fried, LF; Gassman, JJ; Isakova, T; Ix, JH; Larive, B; Middleton, JP; Raj, DS; Raphael, KL; Sprague, SM; Wolf, M | 1 |
| Badve, SV; Toussaint, ND; Yeung, WG | 1 |
| Fujii, H; Goto, K; Goto, S; Kono, K; Nishi, S; Watanabe, K | 1 |
| Nakano, T; Oka, H; Shichijo, S | 1 |
| Kano, M; Katoh, M; Okabe, T; Okazaki, R; Tanaka, Y; Toyoda, H; Ueno, M | 1 |
| Behets, GJ; Blust, R; D'Haese, PC; Finsterle, K; Lamberts, L; Mubiana, KV; Traill, N | 1 |
| Kametani, K; Ota, H; Oyama, T; Shimoda, T; Shiozawa, S; Takahashi, A; Tomori, A; Yamada, T | 1 |
| Fujikawa, K; Hiroyoshi, T; Isoyama, N; Kuro-O, M; Matsuyama, H; Miura, Y; Nagata, Y; Nakamura, K | 1 |
| Fujii, H; Goto, S; Kono, K; Nishi, S; Watanabe, K | 1 |
| Badve, SV; Elder, GJ; Hawley, CM; Lioufas, NM; Pascoe, EM; Pedagogos, E; Toussaint, ND; Valks, A | 1 |
| Block, GA; Chertow, GM; Chonchol, M; de Boer, IH; Ginsberg, C; Hoofnagle, A; Kestenbaum, B; Zelnick, LR | 1 |
| Gräfe, JL; Nguyen, J; Pejović-Milić, A | 1 |
| Badve, SV; Block, GA; Boudville, N; Cameron, JD; Campbell, KL; Chen, SSM; Elder, GJ; Faull, RJ; Hawley, CM; Holt, SG; Hooi, LS; Jackson, D; Jardine, MJ; Johnson, DW; Kerr, PG; Lau, KK; Lioufas, NM; Narayan, O; Pascoe, EM; Pedagogos, E; Perkovic, V; Polkinghorne, KR; Pollock, CA; Reidlinger, D; Robison, L; Smith, ER; Toussaint, ND; Valks, A; Walker, RJ; Wang, AYM | 1 |
| Chen, JP; Huang, H; Koh, KY; Yan, Y; Yang, Y; Zhang, H | 1 |
| Brand, M; Bücker, P; Holling, M; Jeibmann, A; Karst, U; Paulus, W; Radbruch, A; Richter, H; Sperling, M; Van Marck, V | 1 |
| Acedo, IE; de la Mata, DM; Díaz, CC; Irurita, VJ; San Martín, LZ; Santos, ÁP | 1 |
| Chonchol, MB; Gassman, J; Ginsberg, C; Ix, JH; Jamshidian, MS; Larive, B; Raphael, KL | 1 |
| Fujii, H; Hamano, T; Isaka, Y; Koiwa, F; Sakaguchi, Y; Tanaka, R; Tatsugami, F; Teramukai, S; Tomiyama, N; Tsujimoto, Y | 1 |
| Huang, M; Lu, Y; Wu, H; Xia, Y | 1 |
| Akizawa, T; Fukagawa, M; Fukushima, M; Hirakata, H; Kagimura, T; Ogata, H | 1 |
| Wang, L; Yang, J; Zhang, X | 1 |
| Liu, A; Xu, G; Zhao, L | 1 |
| Badve, SV; Block, GA; Elder, GJ; Hawley, CM; Johnson, DW; Lioufas, NM; Pascoe, EM; Toussaint, ND | 1 |
| Choudhury, SR; Karmakar, S; Kaundal, B; Sardoiwala, MN; Srivastava, AK | 1 |
| Liao, PD; Xu, JP; Zeng, RX; Zhang, MZ | 1 |
| Call, DF; Duckworth, OW; Hesterberg, D; Jones, JL; Knappe, DRU; Paterson, AR; Poitras, EP; Zhi, Y | 1 |
| Elder, GJ; Hawley, CM; Hewitson, TD; Holt, SG; Lioufas, NM; Pascoe, EM; Pedagogos, E; Smith, ER; Tiong, MK; Toussaint, ND; Valks, A | 1 |
| Achenbach, H; Murray, RA; Shavkin, A; Sundberg, A; Szabó, T; Uddin, S; Umeh, O; Vergani, A; Wasilewska, A | 1 |
| Akizawa, T; Fukagawa, M; Hirakata, H; Kagimura, T; Ogata, H | 1 |
| Huang, HX; Liu, HX; Yang, XG | 1 |
| Chang, X; Li, M; Shang, S; Xu, W; Yu, M; Zhou, Q | 1 |
82 review(s) available for lanthanum carbonate and lanthanum
| Article | Year |
|---|---|
Hyperphosphataemia in renal failure: causes, consequences and current management.
Topics: Aluminum; Calcinosis; Calcitriol; Calcium; Cardiovascular Diseases; Chlorides; Epoxy Compounds; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Lanthanum; Magnesium; Phosphates; Polyamines; Polyethylenes; Renal Dialysis; Sevelamer; Uronic Acids; Zirconium | 2003 |
[Management of hyperphosphoremia].
Topics: Calcinosis; Calcium; Case Management; Chelating Agents; Chelation Therapy; Epoxy Compounds; Humans; Hyperparathyroidism, Secondary; Iron; Kidney Failure, Chronic; Lanthanum; Phosphorus; Polyamines; Polyethylenes; Sevelamer | 2003 |
Phosphate binder usage in kidney failure patients.
Topics: Acetates; Aluminum Compounds; Calcium Carbonate; Calcium Compounds; Clinical Trials as Topic; Epoxy Compounds; Humans; Iron Compounds; Ketoglutaric Acids; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Polyethylenes; Renal Dialysis; Sevelamer | 2003 |
Lanthanum carbonate (Shire).
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Lanthanum; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency; Structure-Activity Relationship; Treatment Outcome | 2003 |
Lanthanum carbonate.
Topics: Animals; Dose-Response Relationship, Drug; Humans; Lanthanum; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis | 2004 |
Improving phosphate-binder therapy as a way forward.
Topics: Clinical Trials as Topic; Epoxy Compounds; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Polyethylenes; Sevelamer | 2004 |
Lanthanum carbonate: a new phosphate binder.
Topics: Bone and Bones; Buffers; Clinical Trials as Topic; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus; Phosphorus Metabolism Disorders | 2004 |
Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients.
Topics: Clinical Trials as Topic; Humans; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Renal Dialysis; Renal Insufficiency | 2005 |
Blast from the past: the aluminum's ghost on the lanthanum salts.
Topics: Area Under Curve; Chelating Agents; Humans; Kidney Failure, Chronic; Lanthanum; Phosphorus Metabolism Disorders; Renal Dialysis | 2005 |
Lanthanum carbonate (Fosrenol): a novel agent for the treatment of hyperphosphataemia in renal failure and dialysis patients.
Topics: Bone and Bones; Calcium; Humans; Kidney Failure, Chronic; Lanthanum; Parathyroid Hormone; Phosphorus Metabolism Disorders; Randomized Controlled Trials as Topic; Renal Dialysis; Safety | 2005 |
Lanthanum carbonate.
Topics: Animals; Chronic Disease; Clinical Trials as Topic; Humans; Kidney Diseases; Lanthanum; Phosphorus; Treatment Outcome | 2006 |
What's new in clinical pharmacology and therapeutics.
Topics: Acamprosate; Amyloid; Azabicyclo Compounds; Daptomycin; Diphosphonates; Drug Approval; Humans; Ibandronic Acid; Influenza Vaccines; Islet Amyloid Polypeptide; Ketolides; Lanthanum; Memantine; Pharmacology, Clinical; Piperazines; Rifamycins; Rifaximin; Scopolamine Derivatives; Taurine; Tiotropium Bromide; United States; United States Food and Drug Administration | 2006 |
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Topics: Acetates; Aluminum Compounds; Bone Diseases, Metabolic; Calcinosis; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Central Nervous System Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Diet, Protein-Restricted; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Sevelamer | 2006 |
Lanthanum carbonate.
Topics: Animals; Bone and Bones; Clinical Trials as Topic; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Trace Elements | 2006 |
[Phosphate binder up to date].
Topics: Aluminum Hydroxide; Calcium Carbonate; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer | 2007 |
Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Topics: Chelating Agents; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Renal Dialysis; Sevelamer | 2007 |
Emerging drugs for hyperphosphatemia.
Topics: Animals; Atherosclerosis; Calcinosis; Calcium Phosphates; Chelating Agents; Drugs, Investigational; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Renal Dialysis; Saliva; Sevelamer; Uremia | 2007 |
A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate.
Topics: Calcium; Chelating Agents; Clinical Trials as Topic; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer; Treatment Outcome | 2007 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
[K-DOQI guidelines for calcium and phosphorus metabolism in chronic kidney disease: outcomes, compliance and new drugs for treatment].
Topics: Calcium; Cinacalcet; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Treatment Outcome | 2007 |
Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
Topics: Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2008 |
Clinical pharmacokinetics of the phosphate binder lanthanum carbonate.
Topics: Animals; Biological Availability; Clinical Trials as Topic; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Tissue Distribution | 2008 |
[Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
Topics: Animals; Bone and Bones; Chelating Agents; Chelation Therapy; Clinical Trials as Topic; Drug Evaluation, Preclinical; Humans; Hyperphosphatemia; Intestinal Absorption; Kidney Failure, Chronic; Lanthanum; Liver; Nervous System; Phosphorus; Rats; Tissue Distribution | 2008 |
[Lanthanum carbonate in clinical practice].
Topics: Administration, Oral; Chelating Agents; Chelation Therapy; Clinical Trials as Topic; Gastrointestinal Diseases; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Liver; Phosphorus; Tablets | 2008 |
[Control of phosphorus and treatment with vitamin D in chronic kidney disease prior to the start of dialysis].
Topics: Calcifediol; Calcinosis; Calcitriol; Cardiovascular Diseases; Chronic Disease; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphorus; Polyamines; Prevalence; Renal Dialysis; Sevelamer; Vitamin D; Vitamin D Deficiency | 2008 |
[Experimental advances in mineral metabolism].
Topics: Animals; Calcinosis; Calcium; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Chronic Disease; Drug Evaluation, Preclinical; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Intestinal Absorption; Kidney; Kidney Diseases; Lanthanum; Phosphorus; Sodium-Phosphate Cotransporter Proteins | 2008 |
Effects of treatment of renal osteodystrophy on bone histology.
Topics: Bone and Bones; Bone Remodeling; Calcification, Physiologic; Calcitriol; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Humans; Lanthanum; Naphthalenes; Parathyroid Hormone; Phosphates; Polyamines; Sevelamer; Vitamin D | 2008 |
New strategies in treatment of mineral and bone disorders and associated cardiovascular disease in patients with chronic kidney disease.
Topics: Calcinosis; Cardiovascular Diseases; Chronic Disease; Humans; Kidney Diseases; Lanthanum; Minerals; Parathyroid Hormone; Phosphates; Polyamines; Sevelamer | 2008 |
Lanthanum and phosphate: science, policy, and survival.
Topics: Gastrointestinal Tract; Humans; Kidney Failure, Chronic; Lanthanum; Liver; Middle Aged; Minerals; Phosphates | 2009 |
[Management of phosphate in chronic kidney disease--Chemistry and history of phosphate binder].
Topics: Administration, Oral; Aluminum Compounds; Calcium Carbonate; Chronic Disease; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Diseases; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2009 |
[Pharmacodynamic and pharmacokinetic profile of lanthanum carbonate].
Topics: Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Renal Dialysis; Tissue Distribution | 2009 |
[Management of phosphate in chronic kidney disease--Clinical trials of lanthanum carbonate].
Topics: Chronic Disease; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Randomized Controlled Trials as Topic | 2009 |
[Is lanthanum carbonate a safe drug?].
Topics: Administration, Oral; Chronic Disease; Drug-Related Side Effects and Adverse Reactions; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum | 2009 |
[Use of phosphate binder in predialysis patients].
Topics: Calcium Carbonate; Chronic Disease; Dialysis; Drug Approval; Humans; Hyperphosphatemia; Japan; Kidney Diseases; Lanthanum; Polyamines; Prognosis; Sevelamer | 2009 |
[To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients].
Topics: Chronic Disease; Drug Administration Schedule; Hyperphosphatemia; Kidney Diseases; Lanthanum; Patient Compliance; Patient Education as Topic; Polyamines; Sevelamer | 2009 |
Update on the treatment of chronic kidney disease-mineral and bone disorder.
Topics: Aluminum Compounds; Calcinosis; Calcium Carbonate; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cinacalcet; Diet, Protein-Restricted; Dietetics; Humans; Kidney Failure, Chronic; Lanthanum; Naphthalenes; Nephrology; Nutrition Assessment; Nutritive Value; Parathyroidectomy; Patient Care Team; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Sevelamer; Vitamin D | 2009 |
Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Topics: Acetates; Administration, Oral; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Chelating Agents; Drug Monitoring; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Magnesium; Nephrology; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
Therapeutic use of the phosphate binder lanthanum carbonate.
Topics: Bone and Bones; Clinical Trials as Topic; Cognition; Humans; Hyperphosphatemia; Lanthanum; Liver; Phosphates | 2009 |
[Advances in blood purification medicine in 2008].
Topics: Anemia; Hematinics; Hemofiltration; Hepatitis C; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Plasma Exchange; Practice Guidelines as Topic; Renal Dialysis | 2009 |
Oral phosphate binders.
Topics: Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer | 2009 |
Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis.
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Disease Progression; gamma-Glutamyltransferase; Humans; Kidney Failure, Chronic; Lanthanum; Liver; Liver Function Tests; Renal Dialysis | 2009 |
The control of hyperphosphatemia in chronic kidney disease: which phosphate binder?
Topics: Chelating Agents; Chronic Disease; Fibroblast Growth Factor-23; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Polyamines; Renal Dialysis; Sevelamer | 2009 |
[Clinical aspect of recent progress in phosphate metabolism. Management of hyperphosphagtemia].
Topics: Acetates; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Chelating Agents; Drug Design; Gels; Humans; Hyperphosphatemia; Lanthanum; Macromolecular Substances; Phosphorus, Dietary; Polyamines; Polymers; Renal Dialysis; Sevelamer | 2009 |
Benefits and harms of phosphate binders in CKD: a systematic review of randomized controlled trials.
Topics: Acetates; Biomarkers; Bone Density Conservation Agents; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hypercalcemia; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Phosphorus; Polyamines; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Research Design; Sevelamer | 2009 |
Lanthanum carbonate: a review of its use in lowering serum phosphate in patients with end-stage renal disease.
Topics: Administration, Oral; Adult; Animals; Calcium Carbonate; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Time Factors | 2009 |
Phosphate binders in CKD: chalking out the differences.
Topics: Calcium; Calcium Carbonate; Child; Diet; Humans; Hyperparathyroidism; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vascular Diseases | 2010 |
Oral phosphate binders in patients with kidney failure.
Topics: Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer | 2010 |
[Secondary osteoporosis UPDATE. Therapy for bone-mineral disease in CKD-5D patients].
Topics: Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Chronic Disease; Contraindications; Dialysis; Diphosphonates; Fractures, Spontaneous; Kidney Diseases; Lanthanum; Minerals; Polyamines; Sevelamer | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
Topics: Bone Density; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Dialysis; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Practice Guidelines as Topic | 2010 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Lanthanum carbonate and new phosphate binders in patients with chronic kidney disease].
Topics: Cardiovascular Diseases; Chronic Disease; Drug Design; Hyperphosphatemia; Kidney Diseases; Lanthanum; Renal Dialysis; Risk | 2010 |
[Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
Topics: Humans; Hyperphosphatemia; Lanthanum; Renal Insufficiency, Chronic | 2011 |
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
Topics: Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Lanthanum; Membrane Proteins; Naphthalenes; Vascular Calcification; Vitamin D | 2011 |
Phosphate control in peritoneal dialysis.
Topics: Calcium; Humans; Hyperphosphatemia; Lanthanum; Peritoneal Dialysis; Phosphates | 2012 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Pharmacoeconomics in the field of CKD-MBD].
Topics: Bone Diseases, Metabolic; Carbamates; Chelating Agents; Chronic Disease; Cinacalcet; Cost-Benefit Analysis; Humans; Kidney Diseases; Lanthanum; Minerals; Naphthalenes; Parathyroidectomy; Polyamines; Sevelamer; Vitamin D | 2012 |
[Kidney and bone update : the 5-year history and future of CKD-MBD. Progress of phosphate binders].
Topics: Aluminum Hydroxide; Calcium Carbonate; Chelating Agents; Cholestyramine Resin; Chronic Disease; Diet, Protein-Restricted; Drug Design; Humans; Hyperphosphatemia; Ion Exchange Resins; Kidney Diseases; Lanthanum; Phosphorus, Dietary; Polyamines; Sevelamer | 2012 |
Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
Topics: Animals; Bone Diseases, Metabolic; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic | 2012 |
In vitro bioequivalence approach for a locally acting gastrointestinal drug: lanthanum carbonate.
Topics: Gastrointestinal Agents; Humans; Kinetics; Lanthanum; Therapeutic Equivalency | 2013 |
Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Topics: Animals; Binding, Competitive; Bone and Bones; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Progression; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Gene Expression Regulation; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Kidney Tubules; Klotho Proteins; Lanthanum; Models, Biological; Parathyroid Glands; Parathyroid Hormone; Phosphates; Polyamines; Receptor, Fibroblast Growth Factor, Type 1; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency | 2013 |
Effects and safety of lanthanum carbonate in end stage renal disease patients with hyperphosphatemia: a meta-analysis--system review of lanthanum carbonate.
Topics: Bone and Bones; Calcium; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Parathyroid Hormone; Phosphates; Vascular Calcification | 2013 |
Efficacy and tolerability of lanthanum carbonate in treatment of hyperphosphatemia patients receiving dialysis--a systematic review and meta-analysis of randomized controlled trials.
Topics: Calcium; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Placebos; Renal Dialysis; Treatment Outcome | 2014 |
Efficacy and safety of lanthanum carbonate on chronic kidney disease-mineral and bone disorder in dialysis patients: a systematic review.
Topics: China; Chronic Kidney Disease-Mineral and Bone Disorder; Comorbidity; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Humans; Incidence; Lanthanum; Male; Randomized Controlled Trials as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Risk Factors; Survival Rate; Treatment Outcome | 2013 |
Optimal use of phosphate binders in chronic kidney disease.
Topics: Aluminum Hydroxide; Calcium Compounds; Chelating Agents; Humans; Hyperphosphatemia; Lanthanum; Magnesium; Patient Compliance; Phosphates; Polyamines; Practice Guidelines as Topic; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2013 |
The effects of non-calcium-based phosphate binders versus calcium-based phosphate binders on cardiovascular calcification and bone remodeling among dialysis patients: a meta-analysis of randomized trials.
Topics: Biomarkers; Bone Remodeling; Calcium; Calcium Phosphates; Cardiovascular Diseases; Chelating Agents; Humans; Lanthanum; Polyamines; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer; Vascular Calcification | 2014 |
Effect of lanthanum carbonate versus calcium-based phosphate binders in dialysis patients: a meta-analysis.
Topics: Calcium; Calcium Phosphates; Chelating Agents; Dialysis Solutions; Humans; Hypercalcemia; Lanthanum; Parathyroid Hormone; Phosphorus; Renal Dialysis | 2014 |
Efficacy and safety of lanthanum carbonate versus calcium-based phosphate binders in patients with chronic kidney disease: a systematic review and meta-analysis.
Topics: Bone Density; Calcium; Calcium Carbonate; Chelating Agents; Humans; Hypercalcemia; Lanthanum; Parathyroid Hormone; Phosphorus; Radiography; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Vascular Calcification | 2015 |
Restoration of parathyroid function after change of phosphate binder from calcium carbonate to lanthanum carbonate in hemodialysis patients with suppressed serum parathyroid hormone.
Topics: Calcium Carbonate; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Glands; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic | 2015 |
[Vascular Calcification - Pathological Mechanism and Clinical Application - . The effect of phosphate binders on vascular calcification].
Topics: Bone Diseases, Metabolic; Calcium; Cardiovascular Diseases; Chelating Agents; Drug Discovery; Humans; Hyperphosphatemia; Japan; Lanthanum; Polyamines; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2015 |
Novel iron-containing phosphate binders for treatment of hyperphosphatemia.
Topics: Animals; Carbonates; Clinical Trials as Topic; Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Iron; Lanthanum; Magnesium; Phosphates; Renal Insufficiency, Chronic; Sevelamer; Starch; Sucrose | 2015 |
Phosphate binders in chronic kidney disease: a systematic review of recent data.
Topics: Drug Combinations; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Sucrose | 2016 |
Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials.
Topics: Adult; Chelating Agents; Humans; Lanthanum; Network Meta-Analysis; Phosphates; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sevelamer | 2016 |
Lanthanum carbonate: safety data after 10 years.
Topics: Adult; Aged; Animals; Biomarkers; Chelating Agents; Clinical Trials, Phase IV as Topic; Databases, Factual; Female; Humans; Hyperphosphatemia; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Safety; Phosphates; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Lanthanum deposition in the gastrointestinal mucosa and regional lymph nodes in dialysis patients: Analysis of surgically excised specimens and review of the literature.
Topics: Aged; Female; Gastric Mucosa; Humans; Kidney Failure, Chronic; Lanthanum; Lymph Nodes; Male; Renal Dialysis; Stomach Neoplasms | 2016 |
Nutrition Interventions in Chronic Kidney Disease.
Topics: Body Weight; Calcium Carbonate; Cardiovascular Diseases; Chelating Agents; Diet; Diet, Mediterranean; Dyslipidemias; Exercise; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperglycemia; Lanthanum; Phosphorus, Dietary; Protein-Energy Malnutrition; Renal Insufficiency, Chronic; Sodium, Dietary; Water-Electrolyte Balance | 2016 |
A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?
Topics: Calcium Compounds; Chelating Agents; Drug Costs; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Meta-Analysis as Topic; Phosphates; Renal Insufficiency, Chronic; Sevelamer | 2017 |
Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials.
Topics: Calcium; Cardiovascular Diseases; Humans; Hyperphosphatemia; Lanthanum; Mortality; Parathyroid Hormone; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2018 |
A meta-analysis of phosphate binders lanthanum carbonate versus sevelamer hydrochloride in patients with end-stage renal disease undergoing hemodialysis.
Topics: Alkaline Phosphatase; Calcium; Chelating Agents; Cholesterol; Humans; Kidney Failure, Chronic; Lanthanum; Parathyroid Hormone; Phosphates; Renal Dialysis; Sevelamer; Treatment Outcome; Triglycerides | 2018 |
Distribution of lanthanum carbonate in the gastric mucosa confirmed by electron microscopy with a magnified endoscopy: a case report and literature review.
Topics: Aged; Gastric Mucosa; Gastroscopy; Humans; Hyperphosphatemia; Lanthanum; Male; Microscopy, Electron, Scanning; Renal Dialysis | 2020 |
Review of the diagnosis of gastrointestinal lanthanum deposition.
Topics: Atrophy; Gastric Mucosa; Gastrointestinal Diseases; Gastrointestinal Tract; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum | 2020 |
Effects of lanthanum carbonate and calcium carbonate on cardiovascular calcification in hemodialysis patients: A systematic review and meta-analysis.
Topics: Calcium; Calcium Carbonate; Chelating Agents; Fibroblast Growth Factor-23; Humans; Lanthanum; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis | 2022 |
Safety and effectiveness of lanthanum carbonate for hyperphosphatemia in chronic kidney disease (CKD) patients: a meta-analysis.
Topics: Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Hyperphosphatemia; Lanthanum; Observational Studies as Topic; Parathyroid Hormone; Phosphates; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Sevelamer; Treatment Outcome | 2021 |
Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD.
Topics: Chelating Agents; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Insufficiency, Chronic; Sevelamer | 2022 |
Effect of lanthanum carbonate on the progression of coronary artery calcification in hemodialysis patients: A meta-analysis of randomized controlled trials.
Topics: Adult; Calcium; Calcium Carbonate; Chelating Agents; Coronary Vessels; Humans; Lanthanum; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis | 2022 |
87 trial(s) available for lanthanum carbonate and lanthanum
| Article | Year |
|---|---|
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis | 2003 |
Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.
Topics: Aged; Calcium; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Humans; Hypertension; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Nausea; Parathyroid Hormone; Peritoneal Dialysis, Continuous Ambulatory; Phosphates; Renal Dialysis; Safety; Treatment Outcome | 2003 |
Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
Topics: Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Time Factors; Titrimetry | 2004 |
Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis.
Topics: Calcium; Double-Blind Method; Drug Tolerance; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Safety | 2004 |
Control of serum phosphate by oral lanthanum carbonate in patients undergoing haemodialysis and continuous ambulatory peritoneal dialysis in a short-term, placebo-controlled study.
Topics: Administration, Oral; Adult; Aged; Double-Blind Method; Female; Humans; Lanthanum; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Phosphates; Phosphorus Metabolism Disorders; Renal Dialysis; Time Factors | 2005 |
Efficacy, tolerability, and safety of lanthanum carbonate in hyperphosphatemia: a 6-month, randomized, comparative trial versus calcium carbonate.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Calcium Carbonate; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Vitamin D | 2005 |
Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
Topics: Adult; Aged; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome | 2005 |
A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.
Topics: Adolescent; Adult; Aged; Calcium; Dose-Response Relationship, Drug; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Phosphorus Metabolism Disorders; Renal Dialysis; Time Factors; Treatment Outcome | 2005 |
Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
Topics: Adult; Aged; Calcium; Calcium Carbonate; Female; Follow-Up Studies; Humans; Hypercalcemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome | 2006 |
The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
Topics: Adult; Aged; Aged, 80 and over; Biopsy; Calcitriol; Calcium; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus; Renal Dialysis; Treatment Outcome | 2005 |
Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.
Topics: Female; Follow-Up Studies; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Renal Dialysis; Treatment Outcome | 2006 |
Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up.
Topics: Aged; Alkaline Phosphatase; Biomarkers; Calcifediol; Calcitriol; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Follow-Up Studies; Humans; Ilium; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Phosphorus; Renal Dialysis; Treatment Outcome | 2006 |
Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate.
Topics: Administration, Oral; Adult; Biological Availability; Humans; Infusions, Intravenous; Intestinal Absorption; Lanthanum; Male; Reference Values | 2006 |
Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
Topics: Adult; Aged; Cognition; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus Metabolism Disorders; Renal Dialysis | 2007 |
Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Area Under Curve; Biological Availability; Ciprofloxacin; Cross-Over Studies; Drug Interactions; Female; Humans; Intestinal Absorption; Lanthanum; Male; Middle Aged; Time Factors | 2007 |
Lanthanum carbonate effectively controls serum phosphate without affecting serum calcium levels in patients undergoing hemodialysis.
Topics: Adult; Aged; Asian People; Calcium; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Dialysis | 2008 |
Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Calcium; Canada; Chronic Disease; Dose-Response Relationship, Drug; Europe; Female; Humans; Hyperphosphatemia; Israel; Kidney Diseases; Lanthanum; Male; Middle Aged; Outcome Assessment, Health Care; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Treatment Outcome | 2008 |
Higher strength lanthanum carbonate provides serum phosphorus control with a low tablet burden and is preferred by patients and physicians: a multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Drug Administration Schedule; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphorus; Renal Dialysis; Tablets; Time Factors; Treatment Outcome; United States | 2008 |
Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Treatment Outcome | 2008 |
Improvements in renal osteodystrophy in patients treated with lanthanum carbonate for two years.
Topics: Adult; Analysis of Variance; Biomarkers; Bone Remodeling; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Renal Dialysis; Treatment Outcome | 2008 |
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
Topics: Antacids; Calcium Carbonate; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome | 2008 |
Lanthanum carbonate reduces phosphorus burden in patients with CKD stages 3 and 4: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Chronic Disease; Double-Blind Method; Female; Humans; Hyperphosphatemia; Kidney Diseases; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Severity of Illness Index; Time Factors; Treatment Outcome | 2009 |
Colesevelam hydrochloride and lanthanum carbonate interfere with the absorption of levothyroxine.
Topics: Adult; Allylamine; Anticholesteremic Agents; Colesevelam Hydrochloride; Drug Interactions; Female; Humans; Lanthanum; Male; Thyrotropin; Thyroxine | 2009 |
Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Calcium; Chelating Agents; Cross-Over Studies; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.
Topics: Adult; Aged; Aged, 80 and over; Chelating Agents; Chelation Therapy; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus, Dietary; Renal Dialysis; Survival Analysis; Time Factors | 2009 |
Efficacy of chewed vs. crushed lanthanum on phosphorus binding in healthy volunteers.
Topics: Administration, Oral; Adult; Cross-Over Studies; Female; Food; Humans; Lanthanum; Male; Mastication; Phosphorus, Dietary; Powders; Reference Values; Tablets; Young Adult | 2010 |
One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.
Topics: Abdominal Pain; Adult; Aged; Calcium; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Nausea; Parathyroid Hormone; Phosphates; Renal Dialysis; Treatment Outcome; Vomiting | 2010 |
Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease.
Topics: Aged; Chelating Agents; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Kidney Failure, Chronic; Lanthanum; Middle Aged; Phosphorus Compounds; Phosphorus, Dietary; Pilot Projects | 2011 |
Three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients.
Topics: Aged; Asian People; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Treatment Outcome; Vitamin D | 2010 |
The effect of sevelamer carbonate and lanthanum carbonate on the pharmacokinetics of oral calcitriol.
Topics: Administration, Oral; Adult; Calcitriol; Chelating Agents; Cross-Over Studies; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Polyamines; Sevelamer; Tissue Distribution; Young Adult | 2011 |
Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: A pilot randomized controlled trial.
Topics: Adult; Aged; Aortic Diseases; Aortography; Biomarkers; Bone Density; Calcinosis; Calcium; Calcium Carbonate; Chelating Agents; Disease Progression; Female; Humans; Kidney Diseases; Lanthanum; Linear Models; Lumbar Vertebrae; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Renal Dialysis; Time Factors; Tomography, X-Ray Computed; Treatment Outcome; Victoria | 2011 |
Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
Topics: Adult; Chelating Agents; Cross-Over Studies; Female; Humans; Intestinal Absorption; Lanthanum; Male; Middle Aged; Phosphorus, Dietary; Polyamines; Sevelamer; Young Adult | 2011 |
Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Topics: Adult; Aged; Bone and Bones; Chronic Kidney Disease-Mineral and Bone Disorder; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis; Young Adult | 2011 |
Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Biomarkers; Cardiovascular Diseases; Chelating Agents; Cost-Benefit Analysis; Drug Costs; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Models, Economic; Phosphorus; Quality-Adjusted Life Years; Renal Dialysis; Time Factors; Treatment Outcome; Young Adult | 2011 |
Conversion to lanthanum carbonate monotherapy effectively controls serum phosphorus with a reduced tablet burden: a multicenter open-label study.
Topics: Administration, Oral; Adult; Aged; Attitude of Health Personnel; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphates; Phosphorus; Physicians; Tablets; Treatment Outcome | 2011 |
Results of a pilot program to improve phosphorus outcomes in hemodialysis patients.
Topics: Aged; Bone and Bones; Calcium; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Minerals; Nutritional Status; Parathyroid Hormone; Phosphorus; Pilot Projects; Prospective Studies; Renal Dialysis; Serum Albumin | 2012 |
Lanthanum carbonate reduces urine phosphorus excretion: evidence of high-capacity phosphate binding.
Topics: Administration, Oral; Adolescent; Adult; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus; Phosphorus Compounds; Phosphorus, Dietary; Reference Values; Single-Blind Method; Young Adult | 2012 |
Tolerability and efficacy of the intestinal phosphate binder Lantharenol® in cats.
Topics: Animal Feed; Animals; Cats; Dose-Response Relationship, Drug; Feces; Food Additives; Lanthanum; Phosphorus; Phosphorus, Dietary | 2012 |
Assessment of pharmacodynamic equivalence and tolerability of lanthanum carbonate oral powder and tablet formulations: a single-center, randomized, open-label, 2-period crossover study in healthy subjects.
Topics: Administration, Oral; Adult; Cross-Over Studies; Female; Humans; Lanthanum; Male; Powders; Reference Values; Tablets | 2012 |
Dissociation between progression of coronary artery calcification and endothelial function in hemodialysis patients: a prospective pilot study.
Topics: Aged; Biomarkers; Brachial Artery; Calcium; Chelating Agents; Chronic Disease; Coronary Artery Disease; Disease Progression; Endothelium, Vascular; Humans; Iowa; Kidney Diseases; Lanthanum; Middle Aged; Phosphorus; Pilot Projects; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome; Vascular Calcification; Vasodilation | 2012 |
Randomized crossover study of the efficacy and safety of sevelamer hydrochloride and lanthanum carbonate in Japanese patients undergoing hemodialysis.
Topics: Asian People; Calcium; Chelating Agents; Constipation; Cross-Over Studies; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Phosphates; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Treatment Outcome | 2012 |
Effects of phosphate binders in moderate CKD.
Topics: Acetates; Aged; Aged, 80 and over; Bone Density; Calcium Compounds; Chelating Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Polyamines; Renal Insufficiency, Chronic; Sevelamer; Vascular Calcification | 2012 |
Effect of lanthanum carbonate vs. calcium carbonate on serum calcium in hemodialysis patients: a crossover study.
Topics: Acid Phosphatase; Aged; Alkaline Phosphatase; Analysis of Variance; Calcium; Calcium Carbonate; Chelating Agents; Chi-Square Distribution; Cross-Over Studies; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hypercalcemia; Hyperphosphatemia; Isoenzymes; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Tartrate-Resistant Acid Phosphatase; Vitamin D | 2012 |
Effect of lanthanum carbonate on phosphate control in continuous ambulatory peritoneal dialysis patients in Korea: a randomized prospective study.
Topics: Adult; Calcium; Calcium Carbonate; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Peritoneal Dialysis, Continuous Ambulatory; Phosphates; Prospective Studies; Republic of Korea | 2013 |
Lanthanum carbonate for the treatment of hyperphosphatemia in CKD 5D: multicenter, double blind, randomized, controlled trial in mainland China.
Topics: Adolescent; Adult; Aged; China; Comorbidity; Dose-Response Relationship, Drug; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Prevalence; Renal Insufficiency, Chronic; Risk Assessment; Treatment Outcome; Young Adult | 2013 |
The effect of phosphate binders, calcium and lanthanum carbonate on FGF23 levels in chronic kidney disease patients.
Topics: Adult; Aged; Aged, 80 and over; Calcium; Calcium Carbonate; Chelating Agents; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic; Statistics, Nonparametric; Vitamin D | 2013 |
Lanthanum carbonate versus placebo for management of hyperphosphatemia in patients undergoing peritoneal dialysis: a subgroup analysis of a phase 2 randomized controlled study of dialysis patients.
Topics: Double-Blind Method; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Peritoneal Dialysis; Placebo Effect; Treatment Outcome | 2013 |
Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
Topics: Adult; Aged; Chelating Agents; Combined Modality Therapy; Down-Regulation; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Florida; Humans; Lanthanum; Least-Squares Analysis; Male; Middle Aged; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Single-Blind Method; Time Factors; Treatment Outcome | 2013 |
Multicenter study of long-term (two-year) efficacy of lanthanum carbonate.
Topics: Aged; Calcium; Dose-Response Relationship, Drug; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Dialysis; Time Factors; Treatment Outcome | 2013 |
Study of prolonged administration of lanthanum carbonate in dialysis patients.
Topics: Aged; Calcium; Calcium Carbonate; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome | 2013 |
Three-year follow-up of lanthanum carbonate therapy in hemodialysis patients.
Topics: Adult; Aged; Calcium; Calcium Carbonate; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2013 |
Efficacy of continuous oral administration of lanthanum carbonate over 24 months.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Calcium; Calcium Carbonate; Cohort Studies; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Medication Adherence; Middle Aged; Parathyroid Hormone; Phosphates; Polyamines; Practice Guidelines as Topic; Prospective Studies; Renal Dialysis; Sevelamer; Time Factors | 2013 |
Improvement of MBD parameters in dialysis patients by a switch to, and combined use of lanthanum carbonate: Josai Dialysis Forum collaborative study.
Topics: Bone Diseases; Calcium; Calcium Carbonate; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2013 |
Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients.
Topics: Aged; Bone and Bones; Calcium; Calcium Carbonate; Female; Follow-Up Studies; Humans; Inflammation; Interleukin-6; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prospective Studies; Real-Time Polymerase Chain Reaction; Renal Dialysis; RNA, Messenger; Vitamin D | 2013 |
Additional reduction in serum phosphorus levels by pulverized lanthanum carbonate chewable in hemodialysis patients.
Topics: Administration, Oral; Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Mastication; Middle Aged; Phosphorus; Renal Dialysis | 2013 |
Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study.
Topics: Aged; Calcinosis; Calcium; Calcium Carbonate; Chelating Agents; Coronary Artery Disease; Disease Progression; Female; Follow-Up Studies; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pilot Projects; Prospective Studies; Renal Dialysis; Time Factors; Treatment Outcome | 2013 |
Effects of phosphate binder therapy on vascular stiffness in early-stage chronic kidney disease.
Topics: Aged; Biomarkers; Cardiovascular Diseases; Diabetes Complications; Double-Blind Method; Feasibility Studies; Female; Homeostasis; Humans; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Phosphorus, Dietary; Pilot Projects; Renal Insufficiency, Chronic; Risk Factors; Treatment Outcome; Vascular Stiffness | 2013 |
Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
Topics: Adult; Animals; Calcium; Carbamates; Cellulose; Chelating Agents; Female; Gastrointestinal Tract; Humans; Lanthanum; Male; Phosphates; Polyamines; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Sevelamer; Young Adult | 2014 |
The real-world dose-relativity of sevelamer hydrochloride and lanthanum carbonate monotherapy in patients with end-stage renal disease.
Topics: Administration, Oral; Adult; Aged; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Evaluation Studies as Topic; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Polyamines; Renal Dialysis; Risk Assessment; Sevelamer; Severity of Illness Index; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2013 |
Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial.
Topics: Aged; Aortic Diseases; Calcinosis; Calcium Carbonate; Chelating Agents; Diabetes Mellitus, Type 2; Disease Progression; Female; Humans; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Tomography, X-Ray Computed | 2014 |
CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-mineral and bone disorder.
Topics: Adaptor Proteins, Signal Transducing; Adult; Animals; Bone Diseases, Metabolic; Bone Morphogenetic Proteins; Disease Models, Animal; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glucuronidase; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Klotho Proteins; Lanthanum; Male; Mice, Inbred C57BL; Phosphates; Phosphorus, Dietary; Renal Insufficiency, Chronic; Wnt1 Protein | 2014 |
Effect of calcium carbonate combined with calcitonin on hypercalcemia in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; Calcitonin; Calcium; Calcium Carbonate; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Young Adult | 2014 |
Changes in fibroblast growth factor 23 levels in normophosphatemic patients with chronic kidney disease stage 3 treated with lanthanum carbonate: results of the PREFECT study, a phase 2a, double blind, randomized, placebo-controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Male; Middle Aged; Phosphorus; Placebo Effect; Reference Values; Renal Insufficiency, Chronic; Treatment Outcome | 2014 |
Multicenter study on the long-term (3-year) efficacy of lanthanum carbonate in dialysis patients.
Topics: Aged; Calcium; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Time Factors; Treatment Outcome | 2014 |
Clinical effects of long-term (36-month) lanthanum carbonate administration in hemodialysis patients in Japan.
Topics: Aged; Calcium; Calcium Carbonate; Chelating Agents; Dose-Response Relationship, Drug; Female; Humans; Hyperphosphatemia; Japan; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Time Factors; Treatment Outcome | 2014 |
Cost-minimization analysis of lanthanum carbonate versus sevelamer hydrochloride in US patients with end-stage renal disease.
Topics: Adult; Aged; Chelating Agents; Cost Savings; Cost-Benefit Analysis; Drug Costs; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Sevelamer; United States | 2014 |
Efficacy and safety of lanthanum carbonate in pre-dialysis CKD patients with hyperphosphatemia: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Chelating Agents; Double-Blind Method; Female; Humans; Hyperphosphatemia; Intention to Treat Analysis; Japan; Lanthanum; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome | 2014 |
Efficacy, acceptability and tolerability of the new oral phosphate binder Lenziaren® in healthy cats fed a standard diet.
Topics: Animal Feed; Animals; Cats; Diet; Dose-Response Relationship, Drug; Feces; Female; Food Additives; Lanthanum; Male; Phosphates; Phosphorus, Dietary | 2014 |
Design and baseline characteristics of the LANDMARK study.
Topics: Aged; Biomarkers; Calcium Carbonate; Cardiovascular Diseases; Chelating Agents; Clinical Protocols; Disease-Free Survival; Female; Humans; Hyperphosphatemia; Japan; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Research Design; Risk Factors; Time Factors; Treatment Outcome | 2017 |
Effect of high-protein meals during hemodialysis combined with lanthanum carbonate in hypoalbuminemic dialysis patients: findings from the FrEDI randomized controlled trial.
Topics: Bone Diseases; Dietary Proteins; Female; Humans; Hypoalbuminemia; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis | 2017 |
Effects of lanthanum carbonate and calcium carbonate on fibroblast growth factor 23 and hepcidin levels in chronic hemodialysis patients.
Topics: Aged; Biomarkers; Calcium Carbonate; Chelating Agents; Down-Regulation; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hepcidins; Humans; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus, Dietary; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Taiwan; Time Factors; Treatment Outcome | 2017 |
Effect of lanthanum carbonate on coronary artery calcification and bone mineral density in maintenance hemodialysis patients with diabetes complicated with adynamic bone disease: A prospective pilot study.
Topics: Administration, Oral; Biomarkers; Bone Density; Bone Density Conservation Agents; Bone Diseases; Calcinosis; Calcium Carbonate; Coronary Artery Disease; Diabetes Complications; Female; Fibroblast Growth Factor-23; Humans; Lanthanum; Male; Middle Aged; Pilot Projects; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2017 |
Effect of combined vitamin D receptor activator and lanthanum carbonate on serum fibroblast growth factor 23 level in predialysis patients (CVD-LAF study): design and method.
Topics: Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hydroxycholecalciferols; Lanthanum; Receptors, Calcitriol; Renal Dialysis; Renal Insufficiency, Chronic; Research Design | 2018 |
Ferric Citrate Decreases Fibroblast Growth Factor 23 and Improves Erythropoietin Responsiveness in Hemodialysis Patients.
Topics: Erythropoietin; Female; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Lanthanum; Male; Middle Aged; Prospective Studies; Renal Dialysis; Treatment Outcome | 2018 |
Effects of oral activated charcoal on hyperphosphatemia and vascular calcification in Chinese patients with stage 3-4 chronic kidney disease.
Topics: Administration, Oral; Adult; Aged; Biomarkers; Calcium Carbonate; Charcoal; Chelating Agents; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic; Time Factors; Treatment Outcome; Vascular Calcification | 2019 |
Can we IMPROVE cardiovascular outcomes through phosphate lowering in CKD? Rationale and protocol for the IMpact of Phosphate Reduction On Vascular End-points in Chronic Kidney Disease (IMPROVE-CKD) study.
Topics: Adult; Cardiovascular Diseases; Clinical Protocols; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Male; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic | 2019 |
Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
Topics: Adult; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Humans; Lanthanum; Male; Middle Aged; Monte Carlo Method; Niacinamide; Phosphates; Renal Insufficiency, Chronic; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2019 |
The effect of lanthanum carbonate on calciprotein particles in hemodialysis patients.
Topics: Adult; Aged; Aged, 80 and over; alpha-2-HS-Glycoprotein; Calcium; Calcium Carbonate; Drug Substitution; Female; Fibroblast Growth Factor-23; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Prospective Studies; Renal Dialysis | 2020 |
Aortic Calcification and Arterial Stiffness Burden in a Chronic Kidney Disease Cohort with High Cardiovascular Risk: Baseline Characteristics of the Impact of Phosphate Reduction On Vascular End-Points in Chronic Kidney Disease Trial.
Topics: Age Factors; Aged; Aorta; Disease Progression; Female; Fibroblast Growth Factor-23; Glomerular Filtration Rate; Heart Disease Risk Factors; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Pulse Wave Analysis; Sex Factors; Treatment Outcome; Vascular Calcification; Vascular Stiffness | 2020 |
Differential effects of phosphate binders on vitamin D metabolism in chronic kidney disease.
Topics: Acetates; Aged; Calcium Compounds; Chelating Agents; Double-Blind Method; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Prognosis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2020 |
A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
Topics: Aged; Aorta, Abdominal; Double-Blind Method; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pulse Wave Analysis; Renal Insufficiency, Chronic; Tomography, X-Ray Computed; Vascular Calcification | 2020 |
Effect of Lanthanum Carbonate on Blood Pressure in CKD.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Drug Interactions; Female; Humans; Hypertension; Intestinal Absorption; Lanthanum; Male; Middle Aged; Phosphates; Renal Insufficiency, Chronic | 2021 |
Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
Topics: Adult; Aged; Calcinosis; Coronary Artery Disease; Disease Progression; Drug Combinations; Female; Ferric Compounds; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis; Sequestering Agents; Sucrose; Young Adult | 2021 |
Effect of Treating Hyperphosphatemia With Lanthanum Carbonate vs Calcium Carbonate on Cardiovascular Events in Patients With Chronic Kidney Disease Undergoing Hemodialysis: The LANDMARK Randomized Clinical Trial.
Topics: Aged; Calcium Carbonate; Cardiovascular Diseases; Female; Heart Disease Risk Factors; Hip Fractures; Humans; Hyperparathyroidism; Hyperphosphatemia; Incidence; Japan; Lanthanum; Male; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Survival Analysis; Vascular Calcification | 2021 |
Effect of lanthanum carbonate on serum calciprotein particles in patients with stage 3-4 CKD-results from a placebo-controlled randomized trial.
Topics: Aged; Calcium Phosphates; Female; Humans; Lanthanum; Male; Middle Aged; Pulse Wave Analysis; Renal Dialysis; Renal Insufficiency, Chronic | 2023 |
An open-label phase 2 trial to assess the efficacy, safety and pharmacokinetics of lanthanum carbonate in hyperphosphatemic children and adolescents with chronic kidney disease undergoing dialysis.
Topics: Adolescent; Child; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome | 2022 |
Effect of lanthanum carbonate and calcium carbonate on the progression of coronary artery calcification among hemodialysis patients with vascular calcification risk: a randomized controlled trial.
Topics: Calcium; Calcium Carbonate; Chelating Agents; Coronary Artery Disease; Humans; Hyperphosphatemia; Lanthanum; Phosphates; Renal Dialysis; Treatment Outcome; Vascular Calcification | 2022 |
196 other study(ies) available for lanthanum carbonate and lanthanum
| Article | Year |
|---|---|
[Study on antimutagenic effect of lanthanum carbonate in CA test, UDS test and MN test].
Topics: Animals; Antimutagenic Agents; Cells, Cultured; Chromosome Aberrations; Cyclophosphamide; Embryo, Mammalian; Fibroblasts; Humans; Lanthanum; Male; Mice; Micronucleus Tests; Mutagenicity Tests; Nitrogen Mustard Compounds; Ultraviolet Rays | 1997 |
Calcitriol, lanthanum carbonate, and other new phosphate binders in the management of renal osteodystrophy.
Topics: Calcitriol; Chronic Kidney Disease-Mineral and Bone Disorder; Humans; Lanthanum; Peritoneal Dialysis; Phosphates; Vitamin D | 1999 |
Novel phosphate binder is effective in patients on haemodialysis.
Topics: Humans; Lanthanum; Phosphates; Renal Dialysis | 2002 |
Where have all the lanthanum salts gone, long time passing?
Topics: Bone Diseases; Humans; Lanthanum; Renal Dialysis; Treatment Outcome | 2003 |
Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
Topics: Alkaline Phosphatase; Animals; Bone and Bones; Bone Diseases; Bone Remodeling; Calcium; Creatinine; Eating; Kidney Failure, Chronic; Lanthanum; Male; Osteoblasts; Osteocalcin; Parathyroid Hormone; Phosphates; Phosphorus; Rats; Rats, Wistar; Vitamin D | 2004 |
Evaluation of the potential genotoxicity of the phosphate binder lanthanum carbonate.
Topics: Animals; CHO Cells; Cricetinae; Cricetulus; Hypoxanthine Phosphoribosyltransferase; Lanthanum; Male; Mice; Micronucleus Tests; Mutagens; Organophosphates; Phosphates; Rats | 2005 |
Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.
Topics: Administration, Oral; Animals; Body Weight; Intestine, Small; Kidney; Kidney Failure, Chronic; Lanthanum; Male; Organ Size; Rats; Rats, Sprague-Dawley | 2005 |
Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats.
Topics: Animals; Calcification, Physiologic; Diet; Dietary Supplements; Disease Models, Animal; Dose-Response Relationship, Drug; Lanthanum; Male; Nephrectomy; Phosphates; Rats; Rats, Sprague-Dawley; Tibia; Uremia | 2005 |
Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate.
Topics: Administration, Oral; Animals; Bone and Bones; Bone Density; Chronic Kidney Disease-Mineral and Bone Disorder; Kidney Failure, Chronic; Lanthanum; Male; Phosphates; Rats; Rats, Wistar; Spectrometry, X-Ray Emission; Tissue Distribution | 2005 |
The latest findings in basic and clinical nephrology science.
Topics: Anemia; Cinacalcet; Clinical Trials as Topic; Humans; Kidney Diseases; Kidney Transplantation; Lanthanum; Naphthalenes; Renal Dialysis | 2005 |
Effects of efficient phosphate binding on bone in chronic renal failure rats.
Topics: Animals; Bone and Bones; Bone Density; Disease Models, Animal; Epoxy Compounds; Kidney Failure, Chronic; Kidney Function Tests; Lanthanum; Male; Nephrectomy; Osteoporosis; Phosphates; Polyamines; Polyethylenes; Probability; Rats; Rats, Wistar; Sensitivity and Specificity; Sevelamer; Statistics, Nonparametric | 2005 |
Progressive accumulation of lanthanum in the liver of normal and uremic rats.
Topics: Animal Feed; Animals; Creatinine; Female; Femur; Hyperparathyroidism, Secondary; Kidney; Kidney Failure, Chronic; Lanthanum; Liver; Phosphorus; Rats; Rats, Sprague-Dawley; Uremia | 2005 |
The need for contamination control in studies on lanthanum biodisposition.
Topics: Animals; Lanthanum; Reproducibility of Results; Specimen Handling | 2005 |
Lanthanum pharmacokinetics: are rat data misleading?
Topics: Animals; Humans; Lanthanum; Reproducibility of Results; Specimen Handling | 2005 |
The need for careful interpretation of animal data on lanthanum.
Topics: Animals; Body Weight; Lanthanum; Reproducibility of Results; Tissue Distribution | 2005 |
Development and reversibility of impaired mineralization associated with lanthanum carbonate treatment in chronic renal failure rats.
Topics: Animals; Bone and Bones; Bone Density; Calcification, Physiologic; Calcium; Kidney Failure, Chronic; Lanthanum; Male; Phosphates; Rats; Rats, Wistar | 2006 |
Phosphate binders.
Topics: Acetates; Calcium Carbonate; Calcium Compounds; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Polyamines; Sevelamer | 2006 |
Synthesis of nanocrystalline La(Ca)CrO3 through a novel gel combustion process and its characterization.
Topics: Chromium Compounds; Crystallization; Electric Conductivity; Electric Power Supplies; Gels; Hot Temperature; Lanthanum; Materials Testing; Nanostructures; Nanotechnology; Particle Size; Phase Transition | 2006 |
The management of secondary hyperparathyroidism.
Topics: Calcium; Cinacalcet; Diet; Humans; Hyperparathyroidism, Secondary; Lanthanum; Naphthalenes; Phosphates; Vitamin D | 2006 |
Images in clinical medicine. Radiographic appearance of lanthanum.
Topics: Aged, 80 and over; Colon; Humans; Kidney Failure, Chronic; Lanthanum; Male; Phosphates; Phosphorus Metabolism Disorders; Radiography | 2006 |
Enlightenment on liver lanthanum exposure.
Topics: Animal Feed; Animals; Humans; Lanthanum; Liver; Nephrectomy; Rats; Time Factors; Uremia | 2006 |
Lanthanum data in perspective.
Topics: Alanine Transaminase; Animals; Clinical Trials, Phase III as Topic; Female; gamma-Glutamyltransferase; Humans; Intestinal Absorption; Lanthanum; Liver; Male; Randomized Controlled Trials as Topic; Rats; Time Factors; Uremia | 2006 |
Dissolution of functional materials and rare earth oxides into pseudo alveolar fluid.
Topics: Bronchoalveolar Lavage Fluid; Half-Life; Humans; Lanthanum; Metals, Rare Earth; Neodymium; Oxides; Saline Solution, Hypertonic; Solubility; Solvents; Water; Yttrium | 2006 |
Lanthanum carbonate decreases PTH gene expression with no hepatotoxicity in uraemic rats.
Topics: Animals; Biopsy; Disease Models, Animal; Disease Progression; Gene Expression; Kidney Failure, Chronic; Lanthanum; Liver; Magnetic Resonance Imaging; Male; Parathyroid Hormone; Polymerase Chain Reaction; Rats; Rats, Sprague-Dawley; RNA; Uremia | 2007 |
Lanthanum carbonate--new data on parathyroid hormone control without liver damage.
Topics: Humans; Kidney Failure, Chronic; Lanthanum; Nephrectomy; Parathyroid Hormone; Phosphorus Metabolism Disorders; Treatment Outcome | 2007 |
Effect of lanthanum ions (La3+) on ferritin-regulated antioxidant process under PEG stress.
Topics: Antioxidants; Ferritins; Hydroxyl Radical; Lanthanum; Oxidative Stress; Plant Leaves; Plant Proteins; Polyethylene Glycols; Seedlings; Triticum | 2006 |
Lanthanum carbonate: time to abandon prejudices?
Topics: Aluminum; Animals; Bone and Bones; Brain; Humans; Lanthanum; Liver; Phosphates; Phosphorus Metabolism Disorders; Rats | 2007 |
Lanthanum carbonate, body lanthanum accumulation and potential liver toxicity.
Topics: Animals; Kidney Failure, Chronic; Lanthanum; Liver; Organ Size; Rats | 2007 |
Heavy metal--rely on gut feelings: novel diagnostic approach to test drug compliance in patients with lanthanum intake.
Topics: Colon; Feces; Female; Humans; Kidney Failure, Chronic; Lanthanum; Middle Aged; Patient Compliance; Phosphates; Radiography, Abdominal; Renal Dialysis; Tomography, X-Ray Computed | 2007 |
Synthesis, characterization, and photoluminescence property of LaCO3OH microspheres.
Topics: Lanthanum; Luminescence; Microscopy, Electron, Scanning; Microscopy, Electron, Transmission; Microspheres; Photochemistry; Spectroscopy, Fourier Transform Infrared; Temperature; X-Ray Diffraction | 2007 |
Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
Topics: Anions; Bile Acids and Salts; Binding, Competitive; Chelating Agents; Drug Stability; Hydrogen-Ion Concentration; Kinetics; Lanthanum; Models, Chemical; Phosphates; Polyamines; Sevelamer | 2007 |
Systemic lanthanum is excreted in the bile of rats.
Topics: Administration, Oral; Animals; Area Under Curve; Bile; Biological Availability; Dogs; Drug Evaluation, Preclinical; Feces; Female; Glycoproteins; Humans; Injections, Intravenous; Intubation, Gastrointestinal; Lanthanum; Male; Metabolic Clearance Rate; Mice; Protein Binding; Rabbits; Rats; Rats, Sprague-Dawley; Serum Albumin; Sex Factors; Sodium Chloride | 2007 |
Chelation-controlled regioselectivity in the lanthanum-promoted monobenzoylation of monosaccharides in water.
Topics: Benzoates; Chelating Agents; Lanthanum; Monosaccharides; Organophosphates; Water | 2007 |
Optimising the treatment of hyperphosphatemia and vascular calcification in chronic kidney disease.
Topics: Atherosclerosis; Calcinosis; Calcium Phosphates; Chelating Agents; Drugs, Investigational; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Renal Dialysis; Sevelamer; Uremia | 2007 |
Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate.
Topics: Chelating Agents; Contraindications; Fibrosis; Gadolinium; Humans; Kidney Diseases; Kidney Failure, Chronic; Lanthanum; Skin Diseases; United States; United States Food and Drug Administration; Uremia | 2007 |
The case: a peritoneal dialysis patient with an unusual abdominal film. Treatment with lanthanum carbonate.
Topics: Adult; Edema; Female; Humans; Lanthanum; Leg; Peritoneal Dialysis; Peritoneal Dialysis, Continuous Ambulatory; Phosphorus Metabolism Disorders; Radiography, Abdominal; Time Factors | 2007 |
Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
Topics: Calcinosis; Chelating Agents; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Polyamines; Renal Dialysis; Sevelamer; Vascular Diseases | 2007 |
[Radiographic characteristics of lanthanum carbonate absorption].
Topics: Aged; Chelating Agents; Female; Humans; Hyperphosphatemia; Intestinal Absorption; Intestinal Diseases; Kidney Failure, Chronic; Lanthanum; Radiography | 2008 |
Radio-opaque appearance of lanthanum carbonate in a patient with chronic renal failure.
Topics: Aged; Contrast Media; Humans; Kidney Failure, Chronic; Lanthanum; Male; Renal Dialysis; Tomography, X-Ray Computed; Ureterolithiasis | 2008 |
A model of the kinetics of lanthanum in human bone, using data collected during the clinical development of the phosphate binder lanthanum carbonate.
Topics: Administration, Oral; Bone and Bones; Calcium; Drug Administration Schedule; Humans; Injections, Intravenous; Lanthanum; Models, Biological; Phosphates; Randomized Controlled Trials as Topic; Renal Dialysis; Time Factors | 2008 |
Letter regarding 'Advisory about gadolinium calls for caution in the treatment of uremic patients with lanthanum carbonate'.
Topics: Chelating Agents; Contraindications; Contrast Media; Gadolinium; Humans; Kidney Diseases; Kidney Failure, Chronic; Lanthanum; United States; United States Food and Drug Administration; Uremia | 2008 |
Hepatocellular transport and gastrointestinal absorption of lanthanum in chronic renal failure.
Topics: Animals; Bile Canaliculi; Brain; Intestinal Absorption; Kidney Failure, Chronic; Lanthanum; Liver; Lysosomes; Male; Myocardium; Rats; Rats, Inbred Strains; Tissue Distribution; Uremia | 2009 |
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.
Topics: 3' Untranslated Regions; Adenine; Aniline Compounds; Animals; Calcium; Chronic Disease; Disease Models, Animal; Half-Life; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Male; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Phosphates; Phosphorus, Dietary; Propylamines; Rats; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Time Factors; Trans-Activators | 2009 |
Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.
Topics: Animals; Arteries; Bone and Bones; Calcinosis; Chondrogenesis; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Osteogenesis; Phosphates; Rats; Rats, Wistar; Vascular Diseases | 2009 |
Calciphylaxis responsive to lanthanum carbonate (FOSRENOL) therapy.
Topics: Calciphylaxis; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lanthanum; Liver Transplantation; Male; Middle Aged; Renal Dialysis | 2008 |
The use of phosphate binders: data from contributors to the European Practice Database.
Topics: Acetates; Aluminum Compounds; Analysis of Variance; Calcium Carbonate; Calcium Compounds; Chelating Agents; Cross-Sectional Studies; Databases, Factual; Dietetics; Drug Utilization; Europe; Health Care Surveys; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Nephrology; Polyamines; Practice Patterns, Physicians'; Renal Dialysis; Sevelamer; Surveys and Questionnaires; Vitamin D | 2009 |
An unusual abdominal radiograph.
Topics: Abdominal Pain; Colon; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphate-Binding Proteins; Radiography | 2009 |
Precocious puberty and unlicensed paediatric drugs for severe hyperparathyroidism.
Topics: Child, Preschool; Cinacalcet; Drug Approval; Drug Labeling; Hepatocyte Nuclear Factor 1-beta; Humans; Hyperparathyroidism; Kidney Failure, Chronic; Lanthanum; Male; Mutation; Naphthalenes; Puberty, Precocious; Testosterone; Treatment Outcome | 2009 |
[About radio-opaque appearance of a phosphate binder, lanthanum carbonate].
Topics: Chelating Agents; Contrast Media; Humans; Lanthanum; Phosphates; Radiography, Abdominal | 2010 |
Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact?
Topics: Administration, Oral; Animals; Biological Availability; Blood-Brain Barrier; Brain; Dose-Response Relationship, Drug; Drug Contamination; Drug Evaluation, Preclinical; Female; Injections, Intravenous; Lanthanum; Male; Organ Specificity; Rats; Tissue Distribution | 2009 |
A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report.
Topics: Aged; Confusion; Female; Humans; Kidney Failure, Chronic; Lanthanum; Renal Dialysis | 2009 |
Lanthanum deposition in a dialysis patient.
Topics: Adult; Female; Humans; Kidney Failure, Chronic; Lanthanum; Lymph Nodes; Mesentery; Renal Dialysis | 2009 |
[Acute abdominal pain in a 70-year-old patient on hemodialysis].
Topics: Abdominal Pain; Aged; Colectomy; Colon; Diabetic Nephropathies; Diagnosis, Differential; Foreign Bodies; Humans; Hyperphosphatemia; Ischemia; Kidney Failure, Chronic; Lactic Acid; Lanthanum; Male; Mastication; Radiography; Renal Dialysis; Tablets | 2009 |
A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report.
Topics: Confusion; Humans; Kidney Failure, Chronic; Lanthanum; Renal Dialysis | 2009 |
Pie-shaped corpora aliena in a dialysis patient.
Topics: Adult; Foreign Bodies; Humans; Intestines; Lanthanum; Male; Radiography; Renal Dialysis; Tablets | 2009 |
Accumulation of lanthanum carbonate in the digestive tracts.
Topics: Adult; Diverticulum; Female; Gastrointestinal Tract; Humans; Lanthanum; Male; Middle Aged; Renal Dialysis; Tablets; Tomography, X-Ray Computed | 2010 |
Comment on 'Lanthanum deposition in a dialysis patient'.
Topics: Bone Diseases; Humans; Kidney Diseases; Lanthanum; Lymph Nodes; Mesentery; Renal Dialysis | 2010 |
[Hyperamylasaemia and broncoaspiration associated with lanthanum carbonate].
Topics: Fatal Outcome; Female; Humans; Hyperamylasemia; Kidney Failure, Chronic; Lanthanum; Middle Aged; Respiratory Aspiration | 2009 |
Development and validation of an ion chromatography method for the determination of phosphate-binding of lanthanum carbonate.
Topics: Calibration; Chelating Agents; Chromatography, Ion Exchange; Hydrogen-Ion Concentration; Lanthanum; Phosphates; Reproducibility of Results; Time Factors | 2010 |
Lanthanum carbonate is an effective hypophosphatemic agent for hemodialysis patients intolerant of other phosphate binders.
Topics: Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Treatment Outcome | 2010 |
[Radiology image of lanthanum carbonate].
Topics: Abdominal Pain; Artifacts; Chelating Agents; Chelation Therapy; Colon; Diabetic Nephropathies; Diagnosis, Differential; Diverticulitis, Colonic; Diverticulosis, Colonic; Fever; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Tomography, X-Ray Computed | 2010 |
Tissue accumulation of lanthanum as compared to aluminum in rats with chronic renal failure--possible harmful effects after long-term exposure.
Topics: Aluminum; Aluminum Hydroxide; Animals; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Liver; Male; Organ Size; Rats; Rats, Sprague-Dawley | 2010 |
Magnesium carbonate-containing phosphate binder prevents connective tissue mineralization in Abcc6(-/-) mice-potential for treatment of pseudoxanthoma elasticum.
Topics: Animals; ATP-Binding Cassette Transporters; Calcification, Physiologic; Calcium; Connective Tissue; Diet; Femur; Lanthanum; Magnesium; Mice; Mice, Inbred C57BL; Minerals; Multidrug Resistance-Associated Proteins; Phosphates; Phosphorus; Pseudoxanthoma Elasticum; Tomography, X-Ray Computed; Vibrissae | 2009 |
Beam-hardening artifacts on computed tomography images caused by lanthanum carbonate hydrate in a patient on dialysis.
Topics: Aged; Artifacts; Diagnosis, Differential; Foreign Bodies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Renal Dialysis; Tomography, X-Ray Computed | 2010 |
[Intestinal pseudo-occlusion due to lanthanum carbonate].
Topics: Aged; Chelating Agents; Chelation Therapy; Chronic Kidney Disease-Mineral and Bone Disorder; Colonic Diseases; Humans; Hyperphosphatemia; Intestinal Pseudo-Obstruction; Ischemia; Kidney; Kidney Failure, Chronic; Lanthanum; Laparotomy; Male; Phosphates; Radiography; Renal Dialysis | 2010 |
Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders.
Topics: Acetates; Aged; Aged, 80 and over; Calcium Carbonate; Calcium Compounds; Chelating Agents; Humans; Kidney Failure, Chronic; Lanthanum; Middle Aged; New York; Nutritional Status; Phosphates; Phosphorus; Polyamines; Renal Dialysis; Retrospective Studies; Serum Albumin; Sevelamer; Treatment Outcome | 2011 |
[Phosphorus binders: preferences of patients on haemodialysis and its impact on treatment compliance and phosphorus control].
Topics: Acetates; Aged; Aluminum Hydroxide; Calcium Compounds; Chelating Agents; Chelation Therapy; Cohort Studies; Cross-Sectional Studies; Dyspepsia; Female; Health Knowledge, Attitudes, Practice; Humans; Lanthanum; Male; Middle Aged; Patient Compliance; Patient Preference; Phosphorus; Polyamines; Renal Dialysis; Sevelamer; Surveys and Questionnaires; Tablets; Taste | 2010 |
Christmas lights in the gastrointestinal tract.
Topics: Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Radiography, Abdominal | 2010 |
Colonic opacification in a patient with end-stage kidney disease.
Topics: Abdominal Pain; Aged; Colon; Female; Humans; Kidney Failure, Chronic; Lanthanum; Peritoneal Dialysis; Tomography, X-Ray Computed | 2010 |
Perplexing plain abdominal x-ray. Radiographic opacities were due to the lanthanum.
Topics: Abdominal Pain; Barium Sulfate; Colon; Contrast Media; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Radiography | 2011 |
Surface-step-terrace-induced anomalous transport properties in highly epitaxial La0.67Ca0.33MnO3 thin films.
Topics: Crystallization; Electric Conductivity; Electron Transport; Lanthanum; Magnesium Oxide; Materials Testing; Membranes, Artificial | 2010 |
Overestimation of lumbar spine calcium with dual energy X-ray absorptiometry scanning due to the prescription of lanthanum carbonate in patients with chronic kidney disease.
Topics: Absorptiometry, Photon; Bone Density; Diagnostic Errors; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Lumbar Vertebrae; Male; Middle Aged; Osteoporosis | 2010 |
Clinical usefulness of lanthanum carbonate for serum phosphate control in difficult patients.
Topics: Aged; Chelating Agents; Dyspepsia; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Satisfaction; Phosphates; Prospective Studies; Renal Dialysis | 2012 |
Long-term treatment with lanthanum carbonate reduces mineral and bone abnormalities in rats with chronic renal failure.
Topics: Animals; Bone Diseases; Calcification, Physiologic; Calcium; Kidney Failure, Chronic; Lanthanum; Male; Minerals; Phosphorus; Rats; Rats, Wistar | 2011 |
Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients.
Topics: Administration, Oral; Female; Humans; Hyperparathyroidism, Secondary; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Renal Dialysis; Tablets | 2011 |
[Lanthanum carbonate: a novel explanation of a common x-ray image].
Topics: Aged; Colon; Humans; Kidney Failure, Chronic; Lanthanum; Male; Radiography | 2011 |
An unusual hurdle to renal transplantation: speckled abdominal opacities induced by lanthanum carbonate.
Topics: Enema; Female; Humans; Kidney Failure, Chronic; Kidney Transplantation; Lanthanum; Middle Aged; Radiography, Abdominal | 2010 |
Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients.
Topics: Acidosis; Aged; Dialysis Solutions; Female; Humans; Hyperkalemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Polyamines; Prospective Studies; Renal Dialysis; Sevelamer | 2011 |
Pharmacology of the phosphate binder, lanthanum carbonate.
Topics: Aluminum Hydroxide; Animals; Calcium; Calcium Carbonate; Chelating Agents; Dogs; Drug Evaluation, Preclinical; Feces; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Mice; Phosphates; Phosphorus Radioisotopes; Polyamines; Rats; Rats, Sprague-Dawley; Sevelamer | 2011 |
Measurement of serum lanthanum in patients treated with lanthanum carbonate by inductively coupled plasma-mass spectrometry.
Topics: Adult; Aged; Blood Chemical Analysis; Drug Contamination; Female; Humans; Kidney Diseases; Lanthanum; Limit of Detection; Male; Mass Spectrometry; Middle Aged; Renal Dialysis; Reproducibility of Results | 2011 |
Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients.
Topics: Aged; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Humans; Kidney Failure, Chronic; Lanthanum; Longitudinal Studies; Male; Phosphorus; Prognosis; Prospective Studies | 2011 |
Influence of B-site disorder in La0.5Ca0.5Mn(1 - x)B(x)O3 (B = Fe, Ru, Al and Ga) manganites.
Topics: Electromagnetic Fields; Lanthanum; Materials Testing | 2011 |
Lanthanum carbonate, like sevelamer-HCl, retards the progression of vascular calcification and atherosclerosis in uremic apolipoprotein E-deficient mice.
Topics: Analysis of Variance; Animals; Aorta; Apolipoproteins E; Atherosclerosis; Blood Chemical Analysis; Bone Density; Collagen; Disease Models, Animal; Disease Progression; Female; Immunohistochemistry; Lanthanum; Mice; Mice, Inbred Strains; Polyamines; Random Allocation; Reference Values; Renal Insufficiency, Chronic; Sevelamer; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Uremia; Vascular Calcification | 2012 |
Signal intensity of lanthanum carbonate on magnetic resonance images: phantom study.
Topics: Artifacts; Lanthanum; Magnetic Resonance Imaging; Observer Variation; Phantoms, Imaging; Tomography, X-Ray Computed | 2011 |
Combined therapy with lanthanum carbonate and calcium carbonate for hyperphosphatemia decreases serum FGF-23 level independently of calcium and PTH (COLC Study).
Topics: Adult; Aged; Antacids; Calcium; Calcium Carbonate; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Prospective Studies; Renal Dialysis; Treatment Outcome; Young Adult | 2012 |
Phosphate and FGF23 in early CKD: on how to tackle an invisible foe.
Topics: Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Kidney Failure, Chronic; Lanthanum; Male; Phosphorus | 2011 |
Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Topics: Adult; Aged; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cost Savings; Health Care Costs; Hemodialysis Solutions; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Technology Assessment, Biomedical | 2011 |
CKD-mineral and bone disorder: core curriculum 2011.
Topics: Bone Diseases; Calcinosis; Calciphylaxis; Calcitriol; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney; Kidney Failure, Chronic; Kidney Tubules; Lanthanum; Parathyroid Hormone; Parathyroidectomy; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Vitamin D | 2011 |
Radio-opaque fecal impaction and pseudo-occlusion in a dialyzed patient taking lanthanum carbonate.
Topics: Aged; Fecal Impaction; Humans; Kidney Failure, Chronic; Lanthanum; Male; Radiography; Renal Dialysis | 2012 |
Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective.
Topics: Cardiovascular Diseases; Chelating Agents; Cost-Benefit Analysis; Cross-Over Studies; Databases, Factual; Economics, Pharmaceutical; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Markov Chains; Models, Economic; Outcome Assessment, Health Care; Polyamines; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Risk Factors; Sevelamer; United States | 2011 |
Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia?
Topics: Aged; Chelating Agents; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Polyamines; Renal Dialysis; Sevelamer | 2011 |
Intestinal pseudo-obstruction secondary to persistent constipation due to lanthanum carbonate.
Topics: Constipation; Humans; Intestinal Pseudo-Obstruction; Lanthanum; Male; Middle Aged | 2012 |
Pre-existing oral contrast from lanthanum carbonate: a confounding factor in CT mesenteric angiography.
Topics: Administration, Oral; Aged; Angiography; Contrast Media; Gastrointestinal Hemorrhage; Humans; Hyperphosphatemia; Lanthanum; Male; Mesenteric Arteries; Tomography, X-Ray Computed | 2012 |
Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective.
Topics: Canada; Chelating Agents; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Follow-Up Studies; Hospitalization; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Markov Chains; Models, Economic; Polyamines; Quality of Life; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Renal Dialysis; Sevelamer; Survival Rate; Treatment Outcome | 2012 |
Phosphate binders in CKD: bad news or good news?
Topics: Acetates; Calcium Compounds; Chelating Agents; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |
Lanthanum salts improve bone formation in a small animal model of post-menopausal osteoporosis.
Topics: Animals; Bone Density; Calcium; Citrates; Enzyme-Linked Immunosorbent Assay; Female; Lanthanum; Osteoporosis; Ovariectomy; Rats | 2012 |
Unusual image of lanthanum carbonate in the abdominal radiograph.
Topics: Abdominal Pain; Aged; Appendix; Colon; Diarrhea; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Radiography | 2012 |
Effectiveness of lanthanum carbonate treatment used in combination with other phosphate binders in peritoneal dialysis patients.
Topics: Adult; Diabetic Nephropathies; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Multivariate Analysis; Nutritional Status; Parathyroid Hormone; Peritoneal Dialysis; Phosphates; Retrospective Studies | 2012 |
Efficacy and safety of lanthanum carbonate in German patients on dialysis.
Topics: Adult; Aged; Calcium; Female; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Product Surveillance, Postmarketing; Prospective Studies; Renal Dialysis; Tablets | 2012 |
Chronic kidney disease: Phosphate binder therapy--cracks in the tower of strength?
Topics: Acetates; Blood Vessels; Calcinosis; Calcium Compounds; Chelating Agents; Disease Progression; Humans; Hyperphosphatemia; Lanthanum; Phosphate-Binding Proteins; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2012 |
A spangled colon.
Topics: Aged, 80 and over; Calciphylaxis; Carcinoma; Colectomy; Colon; Colonic Neoplasms; Diagnosis, Differential; Humans; Lanthanum; Lower Extremity; Male; Olecranon Process; Pelvis; Prostatic Neoplasms; Radiography; Renal Dialysis; Ulcer; Ulna Fractures; Upper Extremity; Weight Loss | 2012 |
Lanthanum carbonate inhibits intestinal oxalate absorption and prevents nephrocalcinosis after oxalate loading in rats.
Topics: Animals; Intestinal Absorption; Lanthanum; Male; Nephrocalcinosis; Oxalates; Rats; Rats, Sprague-Dawley | 2013 |
Comparative evaluation of the in vitro efficacy of lanthanum carbonate chewable tablets.
Topics: Humans; Hydrogen-Ion Concentration; Kidney Failure, Chronic; Kinetics; Lanthanum; Phosphates; Tablets | 2013 |
Magnetic dynamic properties of electron-doped La(0.23)Ca(0.77)MnO3 nanoparticles.
Topics: Electrons; Lanthanum; Magnetic Fields; Manganese Compounds; Materials Testing; Oxides | 2013 |
Pharmacobezoar in a patient on an oral phosphate binder.
Topics: Aged; Bezoars; Bronchi; Bronchoscopy; Foreign Bodies; Humans; Hyperphosphatemia; Intestinal Obstruction; Lanthanum; Male; Radiography; Rectal Diseases; Tablets | 2013 |
[Radiology image of lanthanum carbonate].
Topics: Abdominal Pain; Aged; Colon; Humans; Lanthanum; Male; Radiography | 2013 |
Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease.
Topics: Aged; Bone and Bones; Bone Diseases; Dose-Response Relationship, Drug; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic | 2013 |
Effects of switch from sevelamer hydrochloride to lanthanum carbonate on serum K and bone metabolic turnover.
Topics: Adult; Aged; Alkaline Phosphatase; Bicarbonates; Bone and Bones; Bone Remodeling; Calcium; Cholesterol; Dose-Response Relationship, Drug; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Polyamines; Potassium; Renal Dialysis; Sevelamer | 2013 |
Correction of hyperphosphatemia suppresses cardiac remodeling in uremic rats.
Topics: Animals; Chelating Agents; Diet; Disease Models, Animal; Extracellular Matrix; Fibroblast Growth Factors; Heart Ventricles; Hyperphosphatemia; Hypertrophy, Left Ventricular; Lanthanum; Male; Nephrectomy; Parathyroid Hormone; Phosphates; Rats, Sprague-Dawley; Uremia; Ventricular Function, Left; Ventricular Remodeling | 2014 |
Ingestion of lanthanum carbonate tablets.
Topics: Humans; Lanthanum; Male; Middle Aged; Tablets | 2013 |
Nonuraemic nonfatal idiopathic calciphylaxis in a kitten.
Topics: Animals; Antifibrinolytic Agents; Calciphylaxis; Cat Diseases; Cats; Chelating Agents; Lanthanum; Male; Thiosulfates; Vitamin K 1 | 2013 |
Hyperphosphatemia and phosphate binders: effectiveness and safety.
Topics: Calcium; Chelating Agents; Diet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Hyperthyroidism; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Renal Insufficiency; Sevelamer; Vascular Calcification | 2014 |
Chewability testing in the development of a chewable tablet for hyperphosphatemia.
Topics: Administration, Oral; Chemistry, Pharmaceutical; Ferric Compounds; Hardness; Hyperphosphatemia; Lanthanum; Mastication; Tablets | 2014 |
High phosphate feeding induced arterial medial calcification in uremic rats: roles of Lanthanum carbonate on protecting vasculature.
Topics: Animals; Calcinosis; Collagen Type II; Core Binding Factor Alpha 1 Subunit; Down-Regulation; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Hyperphosphatemia; Integrin-Binding Sialoprotein; Lanthanum; Male; Osteocalcin; Phosphates; Phosphorus, Dietary; Rats; Transcription Factors; Tunica Media; Uremia | 2013 |
Lanthanum carbonate stimulates bone formation in a rat model of renal insufficiency with low bone turnover.
Topics: Alkaline Phosphatase; Animals; Body Weight; Bone Morphogenetic Proteins; Bone Remodeling; Cell Count; Disease Models, Animal; Femur; Genetic Markers; Lanthanum; Lumbar Vertebrae; Male; Osteocytes; Osteogenesis; Rats, Sprague-Dawley; Renal Insufficiency; Tibia; X-Ray Microtomography | 2014 |
Efficacy of oral powder compared with chewable tablets for lanthanum carbonate administration in hemodialysis patients.
Topics: Administration, Oral; Aged; Calcium; Female; Humans; Lanthanum; Male; Phosphorus; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Tablets; Treatment Outcome | 2013 |
Optimal phosphate control: still an unmet need in chronic kidney disease patients.
Topics: Humans; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphates; Polyamines; Renal Insufficiency, Chronic; Sevelamer | 2014 |
Lanthanum carbonate prevents accelerated medial calcification in uremic rats: role of osteoclast-like activity.
Topics: Acid Phosphatase; Animals; Calcinosis; Cathepsin K; Core Binding Factor Alpha 1 Subunit; Enzyme-Linked Immunosorbent Assay; Hyperphosphatemia; Isoenzymes; Lanthanum; Osteocalcin; Osteoclasts; RANK Ligand; Rats; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; Tartrate-Resistant Acid Phosphatase; Uremia | 2013 |
[Lanthanum carbonate abdominal foreign bodies].
Topics: Abdomen; Aged, 80 and over; Foreign Bodies; Humans; Lanthanum; Male; Radiography, Abdominal; Renal Agents | 2014 |
Fecalith formation and colonic perforation after lanthanum carbonate granules administration.
Topics: Colonic Diseases; Dose-Response Relationship, Drug; Fecal Impaction; Humans; Intestinal Perforation; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Tomography, X-Ray Computed | 2014 |
A comparative study of phosphate binders in patients with end stage kidney disease undergoing hemodialysis.
Topics: Acetates; Adult; Biomarkers; Calcium; Calcium Carbonate; Calcium Compounds; Chelating Agents; Female; Humans; Hypercalcemia; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Polyamines; Renal Dialysis; Retrospective Studies; Sevelamer; Time Factors; Treatment Outcome | 2014 |
A comparison of the long-term effects of lanthanum carbonate and calcium carbonate on the course of chronic renal failure in rats with adriamycin-induced nephropathy.
Topics: Animals; Blood Pressure; Calcium Carbonate; Disease Models, Animal; Doxorubicin; Glucuronidase; Kidney Failure, Chronic; Kidney Function Tests; Klotho Proteins; Lanthanum; Male; Rats; Time Factors | 2014 |
REFOS study: efficacy and safety of lanthanum carbonate in clinical practice in Spain.
Topics: Aged; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Retrospective Studies; Spain; Treatment Outcome | 2014 |
Diffuse colon opacifications due to lanthanum carbonate.
Topics: Aged; Colitis, Ischemic; Colon; Contrast Media; Humans; Lanthanum; Male; Radiography | 2014 |
Increase in the dosage amount of vitamin D3 preparations by switching from calcium carbonate to lanthanum carbonate.
Topics: Administration, Oral; Aged; Alkaline Phosphatase; Calcium; Calcium Carbonate; Cholecalciferol; Dose-Response Relationship, Drug; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphorus; Prognosis; Renal Dialysis; Retrospective Studies | 2014 |
Effects of change in the formulation of lanthanum carbonate on laboratory parameters.
Topics: Aged; Calcium; Chemistry, Pharmaceutical; Female; Geriatric Assessment; Humans; Lanthanum; Male; Middle Aged; Nutrition Assessment; Parathyroid Hormone; Patient Preference; Phosphorus; Renal Dialysis; Retrospective Studies; Serum Albumin; Tablets | 2014 |
Is granular formulation of lanthanum carbonate more effective than chewable tablets?
Topics: Adult; Aged; Chemistry, Pharmaceutical; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Tablets | 2014 |
Questionnaire survey and serum phosphorus levels in maintenance hemodialysis patients switching lanthanum carbonate formulation from chewable tablets to granules.
Topics: Adult; Aged; Aged, 80 and over; Chemistry, Pharmaceutical; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Medication Adherence; Middle Aged; Patient Preference; Phosphorus; Renal Dialysis; Surveys and Questionnaires; Tablets | 2014 |
The utility of the phosphate binder, ferric citrate hydrate (JTT-751), about phosphorus absorption-reducing effect in normal rats.
Topics: Animals; Calcium Carbonate; Ferric Compounds; Intestinal Absorption; Lanthanum; Male; Phosphorus; Rats; Rats, Sprague-Dawley | 2014 |
[Does the presence of contrast material in the digestive tract mean prior barium ingestion?].
Topics: Aged, 80 and over; Barium Sulfate; Constipation; Contrast Media; Eating; Gastrointestinal Tract; Humans; Kidney Failure, Chronic; Lanthanum; Male; Radiography | 2015 |
Real-world dose-relativity, tablet burden, and cost comparison of conversion between sevelamer hydrochloride/carbonate and lanthanum carbonate monotherapies.
Topics: Adult; Costs and Cost Analysis; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Retrospective Studies; Sevelamer; Tablets | 2014 |
Effect of dietary phosphate intake on the circadian rhythm of serum phosphate concentrations in chronic kidney disease: a crossover study.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Circadian Rhythm; Cross-Over Studies; Diet; Female; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Glomerular Filtration Rate; Healthy Volunteers; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Renal Insufficiency, Chronic | 2014 |
Efficacy and acceptability of the new oral phosphate binder Lenziaren(®) in healthy cats fed a renal diet.
Topics: Administration, Oral; Animals; Cats; Diet; Dose-Response Relationship, Drug; Drug Combinations; Female; Ferric Compounds; Lanthanum; Male; Phosphates; Starch; Treatment Outcome | 2015 |
Extensive lanthanum deposition in the gastric mucosa: the first histopathological report.
Topics: Adenocarcinoma; Breast Neoplasms; Female; Gastric Mucosa; Humans; Hyperphosphatemia; Lanthanum; Microscopy, Electron, Scanning; Middle Aged; Neoplasms, Second Primary; Renal Insufficiency, Chronic; Spectrometry, X-Ray Emission; Stomach Neoplasms | 2015 |
Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia.
Topics: Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphorus; Renal Dialysis; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Phosphate binders prevent phosphate-induced cellular senescence of vascular smooth muscle cells and vascular calcification in a modified, adenine-based uremic rat model.
Topics: Adenine; Animal Feed; Animals; Calcinosis; Calcium Carbonate; Cellular Senescence; Disease Models, Animal; Disease Progression; Fibrosis; Immunohistochemistry; Inflammation; Kidney; Kidney Failure, Chronic; Lanthanum; Male; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oxidative Stress; Phosphates; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Signal Transduction; Uremia; Vascular Calcification | 2015 |
Peculiar histiocytic lesions with massive lanthanum deposition in dialysis patients treated with lanthanum carbonate.
Topics: Aged; Duodenum; Female; Gastrointestinal Diseases; Histiocytes; Humans; Immunohistochemistry; Lanthanum; Male; Middle Aged; Renal Dialysis; Renal Insufficiency | 2015 |
Evaluation of intestinal phosphate binding to improve the safety profile of oral sodium phosphate bowel cleansing.
Topics: Acute Kidney Injury; Administration, Oral; Aluminum Hydroxide; Animals; Colonoscopy; Disease Models, Animal; Fibroblast Growth Factor-23; Hyperphosphatemia; Kidney Function Tests; Lanthanum; Male; Phosphates; Rats; Rats, Wistar | 2015 |
Sevalamer Hydrochloride, Sevelamer Carbonate and Lanthanum Carbonate: In Vitro and In Vivo Effects on Gastric Environment.
Topics: Aged; Carbon Dioxide; Chelating Agents; Drug Liberation; Drug Tolerance; Female; Gastric Acidity Determination; Humans; Hydrogen-Ion Concentration; Lanthanum; Male; Phosphorus; Proton Pump Inhibitors; Renal Dialysis; Sevelamer; Stomach | 2015 |
Unexpected action of lanthanum carbonate.
Topics: Aged; Aged, 80 and over; Cross-Sectional Studies; Female; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Renal Insufficiency, Chronic | 2015 |
The effect of lanthanum carbonate on metabolic acidosis in patients with chronic kidney disease stage IV, V and V-D.
Topics: Acidosis; Bicarbonates; Canada; Chelating Agents; Disease Progression; Drug Monitoring; Female; Humans; Hyperphosphatemia; Kidney Function Tests; Lanthanum; Male; Middle Aged; Nutritional Status; Patient Acuity; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Treatment Outcome | 2015 |
Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.
Topics: Bone and Bones; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Phosphates; Renal Dialysis; Time Factors | 2015 |
Effects of Sucroferric Oxyhydroxide Compared to Lanthanum Carbonate and Sevelamer Carbonate on Phosphate Homeostasis and Vascular Calcifications in a Rat Model of Chronic Kidney Failure.
Topics: Animals; Body Weight; Disease Models, Animal; Drug Combinations; Ferric Compounds; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Homeostasis; Kidney Failure, Chronic; Lanthanum; Male; Mortality; Phosphates; Rats, Wistar; Sevelamer; Sucrose; Vascular Calcification | 2015 |
Effects of lanthanum carbonate on vascular calcification in elderly maintenance hemodialysis patients.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Female; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Phosphates; Pruritus; Renal Dialysis; Treatment Outcome; Vascular Calcification | 2015 |
Gastrointestinal symptoms after the substitution of sevelamer hydrochloride with lanthanum carbonate in Japanese patients undergoing hemodialysis.
Topics: Aged; Asian People; Chelating Agents; Diarrhea; Female; Gastrointestinal Diseases; Humans; Lanthanum; Male; Middle Aged; Outpatients; Renal Dialysis; Sevelamer | 2015 |
A Nodular Foreign Body Reaction in a Dialysis Patient Receiving Long-term Treatment With Lanthanum Carbonate.
Topics: Foreign-Body Reaction; Humans; Lanthanum; Male; Middle Aged; Renal Dialysis; Time Factors | 2016 |
Specific Accumulation of Lanthanum Carbonate in the Gastric Mucosal Histiocytes in a Dialysis Patient.
Topics: Biopsy; Carcinoma, Renal Cell; Gastroscopy; Histiocytes; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Kidney Neoplasms; Lanthanum; Male; Microscopy, Electron, Scanning; Middle Aged; Nephrectomy; Renal Dialysis; Stomach Diseases; Tomography, X-Ray Computed | 2015 |
White Gastric Mucosa in a Dialysis Patient.
Topics: Administration, Oral; Aged; Biopsy; Chelating Agents; Endoscopy, Digestive System; Gastric Mucosa; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Microscopy, Electron, Scanning; Renal Dialysis; Spectrometry, X-Ray Emission | 2016 |
Comparison of Phosphate Binding Capacities of PA21, A Novel Phosphate Binder, with those of other Phosphate Binders in vitro and in vivo.
Topics: Administration, Oral; Animals; Calcium Carbonate; Chelating Agents; Drug Combinations; Ferric Compounds; Hyperphosphatemia; Lanthanum; Male; Phosphates; Rats; Rats, Sprague-Dawley; Sevelamer; Sucrose | 2016 |
Impact of Lanthanum Carbonate on Prognosis of Chronic Hemodialysis Patients: A Retrospective Cohort Study (Kawashima Study).
Topics: Aged; Cardiovascular Diseases; Chelating Agents; Cohort Studies; Disease Progression; Female; Humans; Lanthanum; Male; Middle Aged; Phosphorus; Prognosis; Proportional Hazards Models; Renal Dialysis; Retrospective Studies; Treatment Outcome; Vascular Calcification | 2016 |
Lanthanum carbonate has a radiopaque appearance on the plain abdominal radiography.
Topics: Abdomen; Abdominal Pain; Aged, 80 and over; Constipation; Female; Humans; Kidney Failure, Chronic; Lanthanum; Radiography, Abdominal | 2016 |
Lanthanum phosphate deposition in the duodenum.
Topics: Aged; Duodenum; Endoscopy, Gastrointestinal; Gastric Mucosa; Humans; Hyperphosphatemia; Intestinal Mucosa; Lanthanum; Male; Microscopy, Electron, Scanning; Renal Dialysis | 2017 |
Structure and Optimum Luminescence for Nearly Block-Like LaOCl:Eu3+ Nanoparticles.
Topics: Crystallization; Europium; Lanthanum; Light; Luminescence; Luminescent Measurements; Materials Testing; Metal Nanoparticles; Particle Size | 2016 |
Did Lanthanum Carbonate Improve Prognosis in Patients Requiring Chronic Hemodialysis in the Kawashima Study?
Topics: Calcium Carbonate; Humans; Kidney Failure, Chronic; Lanthanum; Phosphates; Prognosis; Renal Dialysis | 2016 |
Haemodialysis: Intradialytic meals: addressing a neglected problem.
Topics: Combined Modality Therapy; Diet, High-Protein; Energy Intake; Humans; Kidney Failure, Chronic; Lanthanum; Malnutrition; Meals; Renal Dialysis; Treatment Outcome | 2017 |
Gastric mucosal status susceptible to lanthanum deposition in patients treated with dialysis and lanthanum carbonate.
Topics: Aged; Aged, 80 and over; Biopsy; Female; Gastric Mucosa; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Stomach Diseases | 2017 |
Effects of phosphate binders on the gastrointestinal absorption of arsenate and of an SGLT2 inhibitor drug on the urinary excretion of arsenite in mice.
Topics: Aluminum Hydroxide; Animals; Arsenates; Arsenites; Benzhydryl Compounds; Female; Gastrointestinal Absorption; Glucosides; Kidney; Lanthanum; Liver; Mice; Phosphates; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors | 2017 |
Lanthanum deposition from oral lanthanum carbonate in the upper gastrointestinal tract.
Topics: Adult; Aged; Female; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Upper Gastrointestinal Tract | 2017 |
Lanthanum Deposition in the Stomach: Usefulness of Scanning Electron Microscopy for Its Detection.
Topics: Aged; Endoscopy, Digestive System; Female; Gastric Mucosa; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Microscopy, Electron, Scanning | 2017 |
A case of lanthanum carbonate ingestion thought to be phlebosclerotic colitis on CT imaging and abdominal radiograph.
Topics: Aged, 80 and over; Colitis; Diagnosis, Differential; Humans; Kidney Failure, Chronic; Lanthanum; Male; Radiography, Abdominal; Tomography, X-Ray Computed | 2017 |
Gastric lanthanosis (lanthanum deposition) in dialysis patients treated with lanthanum carbonate.
Topics: Adult; Aged; Aged, 80 and over; Female; Gastric Mucosa; Histiocytes; Humans; Hyperphosphatemia; Lanthanum; Male; Middle Aged; Renal Dialysis | 2017 |
A Combined Deposition of Lanthanum and β2-Microglobulin-Related Amyloid in the Gastroduodenal Mucosa of Hemodialysis-Dependent Patients: An Immunohistochemical, Electron Microscopic, and Energy Dispersive X-Ray Spectrometric Analysis.
Topics: Adult; Aged; Aged, 80 and over; Amyloid; Amyloidosis; Female; Gastric Mucosa; Humans; Intestinal Mucosa; Lanthanum; Male; Middle Aged; Renal Dialysis | 2017 |
PA21, a novel phosphate binder, improves renal osteodystrophy in rats with chronic renal failure.
Topics: Adenine; Animals; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Models, Animal; Dose-Response Relationship, Drug; Ferric Compounds; Kidney Failure, Chronic; Lanthanum; Male; Parathyroid Hormone; Phosphorus; Rats; Sevelamer; Treatment Outcome | 2017 |
Correlation of lanthanum dosage with lanthanum deposition in the gastroduodenal mucosa of dialysis patients.
Topics: Aged; Dose-Response Relationship, Drug; Female; Gastric Mucosa; Histiocytes; Humans; Hyperphosphatemia; Intestinal Mucosa; Lanthanum; Male; Middle Aged; Renal Dialysis | 2017 |
Effects of Lanthanum Carbonate on Coronary Artery Calcification and Cardiac Abnormalities After Initiating Hemodialysis.
Topics: Adult; Aged; Aged, 80 and over; Calcium Carbonate; Chelating Agents; Coronary Vessels; Female; Fibroblast Growth Factor-23; Humans; Lanthanum; Male; Middle Aged; Parathyroid Hormone; Renal Dialysis; Renal Insufficiency, Chronic; Treatment Outcome; Vascular Calcification | 2018 |
Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.
Topics: Calcium; Chelating Agents; Drug and Narcotic Control; Health Care Costs; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Medicare Part D; Needs Assessment; Phosphorus; Renal Dialysis; Sevelamer; United States | 2018 |
Lanthanum-Induced Mucosal Alterations in the Stomach (Lanthanum Gastropathy): a Comparative Study Using an Animal Model.
Topics: Aged; Animals; Disease Models, Animal; Female; Gastric Mucosa; Gastrointestinal Diseases; Humans; Lanthanum; Male; Microscopy, Electron, Transmission; Middle Aged; Rats; Rats, Wistar; Spectrometry, X-Ray Emission; Stomach | 2018 |
Influence of pH and phosphate concentration on the phosphate binding capacity of five contemporary binders. An in vitro study.
Topics: Acetates; Calcium Carbonate; Calcium Compounds; Chelating Agents; Drug Combinations; Ferric Compounds; Hydrogen-Ion Concentration; Kinetics; Lanthanum; Magnesium; Phosphates; Sevelamer; Sucrose | 2019 |
Gastrointestinal: Lanthanum phosphate deposition in the gastroduodenal mucosa: An unusual cause of epigastric discomfort.
Topics: Abdominal Pain; Adult; Biopsy; Chelating Agents; Duodenum; Endoscopy, Digestive System; Gastric Mucosa; Humans; Immunohistochemistry; Intestinal Mucosa; Lanthanum; Male | 2018 |
Nutritional status and survival of maintenance hemodialysis patients receiving lanthanum carbonate.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Nutritional Status; Phosphates; Phosphorus; Propensity Score; Renal Dialysis; Treatment Outcome | 2019 |
Lanthanum deposition corresponds to white lesions in the stomach.
Topics: Adult; Aged; Biopsy; Endoscopy, Digestive System; Gastric Mucosa; Humans; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Stomach; Stomach Diseases | 2018 |
Phosphate Binders Derived from Natural Ores Contain Many Kinds of Metallic Elements Besides Their Active Ingredient Metals.
Topics: Calcium Carbonate; Chelating Agents; Drug Combinations; Ferric Compounds; Japan; Lanthanum; Metals; Phosphates; Polyamines; Sevelamer; Spectrophotometry, Atomic; Sucrose | 2018 |
Gastric lanthanum phosphate deposition masquerading as white globe appearance.
Topics: Aged; Biopsy; Gastric Mucosa; Humans; Hyperphosphatemia; Lanthanum; Male; Microscopy, Electron, Scanning | 2019 |
Successful Treatment of Tumoral Calcinosis by Lanthanum Carbonate.
Topics: Adult; Calcinosis; Calcium; Female; Gastrointestinal Absorption; Humans; Lanthanum; Lupus Erythematosus, Systemic; Phosphates; Treatment Outcome | 2018 |
Starry-sky bowels.
Topics: Aged, 80 and over; Female; Humans; Lanthanum; Radiography, Abdominal; Tomography, X-Ray Computed | 2018 |
Long-Term Mortality and Bone Safety in Patients with End-Stage Renal Disease Receiving Lanthanum Carbonate.
Topics: Adult; Aged; Bone and Bones; Cohort Studies; Female; Fractures, Bone; Humans; Kaplan-Meier Estimate; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Patient Safety; Renal Agents; Renal Dialysis; Treatment Outcome; United States | 2018 |
Lanthanum carbonate, a phosphate binder, inhibits calcification of implanted aortic allografts in a rat model.
Topics: Allografts; Animals; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Blood Vessel Prosthesis; Calcium; Calcium Carbonate; Lanthanum; Male; Models, Animal; Phosphorus; Rats; Rats, Inbred BN; Rats, Inbred Lew; Transplantation, Homologous; Vascular Calcification | 2019 |
Relationship between Gut Microbiota and Phosphorus Metabolism in Hemodialysis Patients: A Preliminary Exploration.
Topics: Child; Female; Gastrointestinal Microbiome; Humans; Lanthanum; Male; Middle Aged; Phosphorus; Prospective Studies; Renal Dialysis; Risk Factors; Uremia | 2018 |
Lanthanum phosphate binder-induced iron deficiency anaemia.
Topics: Aged; Anemia, Iron-Deficiency; Gastric Mucosa; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male | 2019 |
An incidental finding of metallic objects in a patient with chronic renal failure.
Topics: Administration, Oral; Aged; Foreign-Body Reaction; Humans; Incidental Findings; Kidney Failure, Chronic; Kidney Transplantation; Lanthanum; Male; Tomography, X-Ray Computed | 2019 |
Lanthanum deposition in the gastric mucosa in a patient treated with haemodialysis.
Topics: Aged; Endoscopy, Digestive System; Gastric Mucosa; Histiocytes; Humans; Kidney Failure, Chronic; Lanthanum; Male | 2019 |
Dual Inhibition of Gastrointestinal Phosphate Absorption: More Questions Than Answers.
Topics: Fibroblast Growth Factors; Humans; Hyperphosphatemia; Lanthanum; Niacinamide; Phosphates; Renal Insufficiency, Chronic | 2019 |
Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients.
Topics: Aged; Biomarkers; Bone and Bones; Bone Density; Bone Remodeling; Calcium; Calcium Carbonate; Female; Humans; Lanthanum; Male; Middle Aged; Osteocalcin; Parathyroid Hormone; Phosphates; Renal Dialysis; Renal Insufficiency, Chronic; Tartrate-Resistant Acid Phosphatase | 2019 |
Case of Chronic Cough Caused by Accidental Inhalation of Lanthanum Carbonate Granules.
Topics: Cough; Female; Humans; Inhalation; Lanthanum; Middle Aged | 2020 |
[Studies of the Various Chronic Kidney Failure Rat Models and Hemodialysis Mini-pig Model for the Evaluation of Anti-hyperphosphatemia Drugs].
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Rats, Wistar; Renal Dialysis; Swine; Swine, Miniature; Therapeutic Equivalency | 2019 |
Use of lanthanum for water treatment A matter of concern?
Topics: Animals; Bentonite; Eutrophication; Lanthanum; Liver; Phosphorus; Rats; Water Purification | 2020 |
Comparison of the effects of lanthanum carbonate and calcium carbonate on the progression of cardiac valvular calcification after initiation of hemodialysis.
Topics: Aged; Aged, 80 and over; Biomarkers; Calcinosis; Calcium Carbonate; Chelating Agents; Disease Progression; Female; Heart Valve Diseases; Humans; Kidney Diseases; Lanthanum; Male; Middle Aged; Phosphorus; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Time Factors; Treatment Outcome | 2020 |
Investigating coherent normalization and dosimetry for the
Topics: Bone and Bones; Child, Preschool; Fluorescence; Humans; Hyperphosphatemia; Lanthanum; Monte Carlo Method; Phantoms, Imaging; Radiation Dosage; Spectrometry, X-Ray Emission; X-Rays | 2020 |
Great enhancement in phosphate uptake onto lanthanum carbonate grafted microfibrous composite under a low-voltage electrostatic field.
Topics: Adsorption; Hydrogen-Ion Concentration; Kinetics; Lanthanum; Phosphates; Static Electricity; Water Pollutants, Chemical | 2021 |
Deposition patterns of iatrogenic lanthanum and gadolinium in the human body depend on delivered chemical binding forms.
Topics: Contrast Media; Gadolinium; Humans; Lanthanum; Lasers; Male; Mass Spectrometry; Middle Aged; Tissue Distribution | 2021 |
Massive upper gastrointestinal bleeding due to gastric lanthanosis.
Topics: Gastrointestinal Hemorrhage; Gastroscopy; Humans; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Stomach Diseases | 2021 |
Strong adsorption of phosphate by amorphous lanthanum carbonate nano-adsorbents.
Topics: Adsorption; Hydrogen-Ion Concentration; Kinetics; Lanthanum; Phosphates; Wastewater; Water Pollutants, Chemical | 2021 |
Coupled catalytic dephosphorylation and complex phosphate ion-exchange in networked hierarchical lanthanum carbonate grafted asymmetric bio-composite membrane.
Topics: Adsorption; Catalysis; Ecosystem; Hydrogen-Ion Concentration; Ion Exchange; Kinetics; Lanthanum; Organophosphates; Phosphates; Water Pollutants, Chemical | 2022 |
Mechanisms of orthophosphate removal from water by lanthanum carbonate and other lanthanum-containing materials.
Topics: Adsorption; Lanthanum; Phosphates; Water; Water Pollutants, Chemical | 2022 |
Lanthanum carbonate, a potent and selective phosphate binder, is transported and absorbed mainly via M cells in gastrointestinal tract.
Topics: Animals; Caco-2 Cells; Gastrointestinal Tract; Humans; Lanthanum; M Cells; Mice; Phosphates | 2023 |
A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.
Topics: Humans; Hyperphosphatemia; Intestinal Obstruction; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Renal Dialysis; Renal Insufficiency, Chronic; Tablets | 2023 |